haloperidol has been researched along with Dyskinesia, Drug-Induced in 559 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this multicenter, phase 3, randomized, double-blind, parallel-group study, only patients with DSM-IV schizophrenia who had failed an adequate antipsychotic treatment within the previous 6 months and who had not responded positively to haloperidol during screening were eligible for enrollment." | 9.15 | A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. ( Buckley, PF; Daniel, DG; Kane, JM; Potkin, SG, 2011) |
| "To better understand the efficacy and tolerability of atypical antipsychotics among racial groups, we reviewed data from four short-term (4-6 weeks), fixed-dose, placebo-controlled trials of ziprasidone for black, white, and overall populations of patients with schizophrenia." | 9.14 | Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies. ( Herman, BK; Lawson, WB; Lazariciu, I; Loebel, A; Malik, M, 2009) |
| "To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol." | 9.10 | Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. ( Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R, 2003) |
| "The purpose of this study was to evaluate the clinical safety and efficacy of risperidone compared to haloperidol in patients with treatment-refractory schizophrenia." | 9.09 | Risperidone in treatment-refractory schizophrenia. ( Green, MF; Marder, SR; Marshall, BD; Mintz, J; Wirshing, DA; Wirshing, WC, 1999) |
| "Pramipexole, a presynaptic dopamine D2/D3 autoreceptor agonist, has been given to haloperidol-treated patients with schizophrenia (n = 15) in an effort to ameliorate residual positive and negative symptoms that have not been satisfactorily influenced by haloperidol alone." | 9.08 | Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy. ( Barnas, C; Heiden, A; Kasper, S; Laakmann, G; Pfolz, H; Volz, HP; Zeit, H, 1997) |
| "This multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of three doses of sertindole (12, 20, and 24 mg/day) and haloperidol (4, 8, and 16 mg/day) in the treatment of psychotic symptoms for 497 hospitalized patients with schizophrenia." | 9.08 | Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. ( Daniel, DG; Kane, JM; Kashkin, KB; Mack, RJ; Sebree, TB; Tamminga, CA; Wallin, BA; Wozniak, PJ; Zimbroff, DL, 1997) |
| "We conducted a placebo-controlled, randomized, double-blind, 8-week trial of sertraline added to haloperidol treatment in patients with schizophrenia to evaluate changes in clinical measures and pharmacokinetic interactions with haloperidol." | 9.08 | A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. ( Kim, YK; Lee, MS; Lee, SK; Suh, KY, 1998) |
| "The efficacy and safety of remoxipride in the treatment of schizophrenia were compared with those of haloperidol in a multicentre double-blind 6-week study which was randomized with a parallel group design and was preceded by a washout period." | 9.06 | Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison. ( Chanas, A; Deo, R; Edwards, JG; Levine, S; Mitchell, M; Plant, I; Rastogi, SC; Soni, S, 1990) |
| "Ninety-two patients with schizophrenia were included in a double-blind multicentre parallel-group trial comparing remoxipride and haloperidol." | 9.06 | Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study. ( Ahlfors, UG; Appelberg, B; Hagert, U; Harma, P; Katila, H; Mahlanen, A; Mehtonen, OP; Naukkarinen, H; Outakoski, J; Rimön, R, 1990) |
| "To review the effects in clinical response of haloperidol and low-potency antipsychotics for people with schizophrenia." | 8.90 | Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. ( Engel, RR; Huhn, M; Kissling, W; Leucht, S; Tardy, M, 2014) |
| "To comparatively assess the incidence of tardive dyskinesia in patients with schizophrenia receiving either aripiprazole or haloperidol." | 7.74 | Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. ( Eudicone, JM; Kim, E; Miller, DD; Pikalov, A, 2007) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 7.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| "Measurement of plasma prolactin (PRL) concentration and plasma homovanillic acid (HVA) concentration was performed in 24 patients with schizophrenia during maintenance haloperidol treatment." | 7.68 | Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia. ( Csernansky, JG; Newcomer, JW; Riney, SJ; Vinogradov, S, 1992) |
| " Oscillations in forelimb force during this performance were spectrally analyzed to describe the tremorogenic effects of haloperidol (0." | 7.68 | A new rodent model for neuroleptic-induced pseudo-parkinsonism: low doses of haloperidol increase forelimb tremor in the rat. ( Fowler, SC; Liao, RM; Skjoldager, P, 1990) |
| "Risperidone was hypothesized to have better extrapyramidal tolerability and efficacy in treating negative symptoms." | 6.73 | Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. ( Braus, DF; Buchkremer, G; Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klosterkötter, J; Kühn, KU; Maier, W; Möller, HJ; Ohmann, C; Riedel, M; Riesbeck, M; Schlösser, R; Schneider, F; Wickelmaier, F, 2008) |
| "Haloperidol was associated with a sustained hyperprolactinemia, unlike ziprasidone, where only transient elevations in prolactin that returned to normal within the dosing interval were observed." | 6.69 | An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. ( Goff, DC; Herz, L; Kletti, N; Ko, GN; Lapierre, K; Law, CG; Posever, T; Simmons, J; Wilner, KD, 1998) |
| "Haloperidol treated patients reported more tiredness and drowsiness than remoxipride treated patients." | 6.67 | A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. ( Beckmann, H; Bunse, J; Dittmann, V; Klieser, E; König, P; Laux, G; Schöny, HW; Schröder, HG; Schubert, H; Unterweger, B, 1990) |
| " The dosage equivalency of haloperidol decanoate (1." | 6.66 | A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. ( Annable, L; Campbell, W; Chouinard, G, 1989) |
| "Haloperidol patients were more often single and institutionalised, less educated, had more residual schizophrenia, were longer hospitalised in the previous year, took more corrective and psychotropic drugs and had more extrapyramidal symptoms (EPS) and gynaecomastia (all significantly)." | 5.35 | Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. ( Albert, A; De Graeve, D; Gillain, B; Peuskens, J; Van Vleymen, B, 2009) |
| "With the background of a number of meta-analyses on the optimal neuroleptic dosages [1,2] the average daily dosage for the treatment of acute schizophrenic episodes recommended in the internal treatment guidelines of our psychiatric clinic was reduced from 24 mg to 15 mg haloperidol equivalent." | 5.31 | ["More is less": a retrospective study of haloperidol dosages in acute schizophrenia]. ( Kissling, W; Kockott, G; Müller, R, 2000) |
| "In this multicenter, phase 3, randomized, double-blind, parallel-group study, only patients with DSM-IV schizophrenia who had failed an adequate antipsychotic treatment within the previous 6 months and who had not responded positively to haloperidol during screening were eligible for enrollment." | 5.15 | A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. ( Buckley, PF; Daniel, DG; Kane, JM; Potkin, SG, 2011) |
| "To better understand the efficacy and tolerability of atypical antipsychotics among racial groups, we reviewed data from four short-term (4-6 weeks), fixed-dose, placebo-controlled trials of ziprasidone for black, white, and overall populations of patients with schizophrenia." | 5.14 | Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies. ( Herman, BK; Lawson, WB; Lazariciu, I; Loebel, A; Malik, M, 2009) |
| "Acutely agitated patients with schizophrenia or schizoaffective disorder treated with aripiprazole IM or haloperidol IM demonstrated similar effective and safe transition to their respective oral formulations." | 5.12 | Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. ( Allen, MH; Crandall, DT; Currier, GW; Daniel, DG; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL, 2007) |
| "While haloperidol is still widely used in the treatment of psychoses, the optimal daily dose remains a topic of controversy, particularly in first-episode psychosis." | 5.11 | A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. ( Emsley, R; Jadri Turner, H; Keyter, N; Oosthuizen, P, 2004) |
| "This 12-month, randomized, investigator-blinded study compared the efficacy of quetiapine (N = 22) and haloperidol (N = 23) in treating patients with DSM-IV schizophrenia or schizoaffective disorder and established tardive dyskinesia." | 5.11 | A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. ( Botha, K; Emsley, R; Oosthuizen, PP; Schronen, J; Smit, R; Turner, HJ, 2004) |
| "To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol." | 5.10 | Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. ( Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R, 2003) |
| "The purpose of this study was to evaluate the clinical safety and efficacy of risperidone compared to haloperidol in patients with treatment-refractory schizophrenia." | 5.09 | Risperidone in treatment-refractory schizophrenia. ( Green, MF; Marder, SR; Marshall, BD; Mintz, J; Wirshing, DA; Wirshing, WC, 1999) |
| " In this long-term, open, randomised, multicentre trial, patients with chronic or subchronic schizophrenia received amisulpride (n =370) or haloperidol (n = 118) for 12 months." | 5.09 | Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. ( Colonna, L; Dondey-Nouvel, L; Rein, W; Saleem, P, 2000) |
| " Patients with schizophrenia and related disorders (ICD-10) who were taking haloperidol (N = 94; mean dose = 12." | 5.09 | Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America. ( Alvarez, N; Costa e Silva, JA; Cousins, L; Gattaz, WF; Larach, V; Mazzotti, G; Oliva, D; Ospina, J; Starkstein, S; Taylor, CC; Tohen, M; Tran, PV; Wang, J, 2001) |
| "5 mg/day [Olz-H]) to a dosage range of haloperidol (15 +/- 5 mg/day [Hal]) and to placebo in the treatment of 335 patients who met the DSM-III-R criteria for schizophrenia." | 5.08 | Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. ( Beasley, CM; Hamilton, S; Sanger, T; Satterlee, W; Tollefson, G; Tran, P, 1996) |
| "The subjects were 62 patients hospitalized for acute exacerbations of schizophrenia and were randomly assigned to receive risperidone (mean dose, 7." | 5.08 | Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. ( Azorin, JM; Blin, O; Bouhours, P, 1996) |
| "Pramipexole, a presynaptic dopamine D2/D3 autoreceptor agonist, has been given to haloperidol-treated patients with schizophrenia (n = 15) in an effort to ameliorate residual positive and negative symptoms that have not been satisfactorily influenced by haloperidol alone." | 5.08 | Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy. ( Barnas, C; Heiden, A; Kasper, S; Laakmann, G; Pfolz, H; Volz, HP; Zeit, H, 1997) |
| "This multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of three doses of sertindole (12, 20, and 24 mg/day) and haloperidol (4, 8, and 16 mg/day) in the treatment of psychotic symptoms for 497 hospitalized patients with schizophrenia." | 5.08 | Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. ( Daniel, DG; Kane, JM; Kashkin, KB; Mack, RJ; Sebree, TB; Tamminga, CA; Wallin, BA; Wozniak, PJ; Zimbroff, DL, 1997) |
| "Data were analyzed from three actively controlled and blind long-term responder studies of subjects meeting DSM-III-R criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder treated with olanzapine (N = 707, up to 20 mg/day, 237 median days of exposure) or haloperidol (N = 197, up to 20 mg/day, 203 median days of exposure) who did not have evidence of tardive dyskinesia at baseline." | 5.08 | Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. ( Beasley, CM; Potvin, JH; Tamura, RN; Tollefson, GD; Tran, PV, 1997) |
| "We conducted a placebo-controlled, randomized, double-blind, 8-week trial of sertraline added to haloperidol treatment in patients with schizophrenia to evaluate changes in clinical measures and pharmacokinetic interactions with haloperidol." | 5.08 | A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. ( Kim, YK; Lee, MS; Lee, SK; Suh, KY, 1998) |
| "In a double-blind study, 135 inpatients with a diagnosis of chronic schizophrenia were randomly assigned to 8 weeks of treatment with one of six parallel treatments: risperidone (a new central 5-hydroxytryptamine2 and dopamine D2 antagonist), 2, 6, 10, 16 mg/day; haloperidol, 20 mg/day; or placebo, after a single-blind placebo washout period." | 5.07 | A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. ( Addington, D; Arnott, W; Beauclair, L; Bloom, D; Chouinard, G; Jones, B; Labelle, A; MacEwan, GW; Remington, G, 1993) |
| "Clozapine has long been considered a useful treatment in patients who have schizophrenia with the neuroleptic-induced delayed-onset side effect tardive dyskinesia." | 5.07 | Clozapine in tardive dyskinesia: observations from human and animal model studies. ( Gao, XM; Kakigi, T; Moran, M; Tamminga, CA; Thaker, GK, 1994) |
| "Two hundred and forty-two patients with acute schizophrenia were enrolled in a double-blind, comparative, dose-finding study of a novel antipsychotic, remoxipride." | 5.07 | A dose-finding study with remoxipride in the acute treatment of schizophrenic patients. ( Ancill, R; Awad, G; Bakish, D; Beaudry, P; Bloom, D; Chandrasena, R; Das, M; Durand, C; Elliott, D; Lapierre, YD, 1992) |
| "Plasma prolactin concentration (pPRL), plasma homovanillic acid concentration (pHVA), and symptomatology were measured in 24 male subjects with schizophrenia during maintenance haloperidol treatment." | 5.07 | Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease. ( Csernansky, JG; Newcomer, JW; Riney, SJ; Vinogradov, S, 1992) |
| "In an open label study, two fixed doses of nifedipine (30 mg and 60 mg daily) were added to the usual antipsychotic drug treatments of 10 patients suffering from chronic schizophrenia." | 5.07 | Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients. ( Eyles, D; Pond, SM; Stedman, TJ; Welham, JL; Whiteford, HA, 1991) |
| "Twenty-nine inpatients with major psychotic disorders were treated for 14 days with a clinician-determined dose of haloperidol and with either benztropine or placebo given by double-blind random assignment on days 1 through 7." | 5.07 | The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. ( Arana, GW; Dupont, R; Goff, DC; Greenblatt, DJ; Harmatz, JS; Ornsteen, M; Shader, RI, 1991) |
| "The efficacy and safety of remoxipride in the treatment of schizophrenia were compared with those of haloperidol in a multicentre double-blind 6-week study which was randomized with a parallel group design and was preceded by a washout period." | 5.06 | Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison. ( Chanas, A; Deo, R; Edwards, JG; Levine, S; Mitchell, M; Plant, I; Rastogi, SC; Soni, S, 1990) |
| "Ninety-two patients with schizophrenia were included in a double-blind multicentre parallel-group trial comparing remoxipride and haloperidol." | 5.06 | Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study. ( Ahlfors, UG; Appelberg, B; Hagert, U; Harma, P; Katila, H; Mahlanen, A; Mehtonen, OP; Naukkarinen, H; Outakoski, J; Rimön, R, 1990) |
| "We describe a long-term follow-up study (1-15 years) of 33 patients with Tourette syndrome who were treated with pimozide (2-18 mg), haloperidol (2-15 mg), or no drugs." | 5.06 | Tourette syndrome: a follow-up study. ( Lang, A; Moldofsky, H; Musisi, S; Sandor, P, 1990) |
| "To review the effects in clinical response of haloperidol and low-potency antipsychotics for people with schizophrenia." | 4.90 | Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. ( Engel, RR; Huhn, M; Kissling, W; Leucht, S; Tardy, M, 2014) |
| " In the Gilles-de-la-Tourette syndrome nicotine reduces the severity and frequency of the tics given in combination with haloperidol." | 4.79 | [Nicotine in neuropsychiatric movement disorders]. ( Erdmann, R, 1996) |
| "Intravenous haloperidol is recommended as the drug of choice to treat delirium in ICU patients." | 4.79 | Movement disorders associated with withdrawal from high-dose intravenous haloperidol therapy in delirious ICU patients. ( Fraser, GL; Richen, P; Riker, RR, 1997) |
| " In the field of antipsychotics, the first clinical trial on haloperidol decanoate in the treatment of schizophrenia was performed and the daily changes of blood concentrations of haloperidol were also observed." | 4.76 | [Recent advances in clinical psychopharmacology]. ( Mori, A, 1984) |
| " He developed partial complex status epilepticus, requiring benzodiazepines, phenytoin, propofol and intubation." | 3.81 | Medication-induced acute dystonic reaction: the challenge of diagnosing movement disorders in the intensive care unit. ( Digby, G; Jalini, S; Taylor, S, 2015) |
| "In total 56 patients acutely treated with haloperidol or risperidone either for the first episode of schizophrenia, schizophreniform or schizoaffective disorders, or for the relapse of these psychotic disorders after tapering their maintenance treatment, were genotyped for the 5-HTTLPR L and S alleles and for the new A/G functional variant within the L alelle (La/g)." | 3.74 | Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes. ( Dolzan, V; Kastelic, M; Koprivsek, J; Mandelli, L; Plesnicar, BK; Serretti, A, 2008) |
| "The undesired extrapyramidal movement disorders observed with long term treatment with haloperidol have been associated with striatal neurodegeneration." | 3.74 | Activation of striatal inflammatory mediators and caspase-3 is central to haloperidol-induced orofacial dyskinesia. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2008) |
| " Auditory hallucinations had developed 25 years previously, for which haloperidol had been prescribed." | 3.74 | Methamphetamine psychosis in which tardive dystonia was successfully treated with clonazepam. ( Inada, T; Oda, T; Yamamoto, N, 2007) |
| "To comparatively assess the incidence of tardive dyskinesia in patients with schizophrenia receiving either aripiprazole or haloperidol." | 3.74 | Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. ( Eudicone, JM; Kim, E; Miller, DD; Pikalov, A, 2007) |
| " We report on a young Chinese man with bipolar disorder who developed TD after haloperidol treatment, involving the trunk, limbs, and orofacial area." | 3.73 | A blessing in disguise: resolution of tardive dyskinesia with development of cervical myelitis. ( Lim, EC; Seet, RC; Wilder-Smith, EP, 2006) |
| "Fifty-seven subjects with first-episode psychosis and a DSM-IV diagnosis of schizophreniform disorder, schizophrenia, or schizoaffective disorder were treated according to a fixed protocol with a mean dose of haloperidol of 1." | 3.72 | Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. ( Emsley, RA; Keyter, N; Maritz, JS; Oosthuizen, PP; Turner, JA, 2003) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 3.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| " We assessed the relationship between pre- and perinatal complications and TD/WD in a sample of 118 children with autism who participated in an ongoing long-term prospective study of the efficacy and safety of haloperidol." | 3.69 | Haloperidol-related dyskinesias and pre- and perinatal complications in autistic children. ( Adams, PB; Armenteros, JL; Campbell, M; Eisenberg, ZW, 1995) |
| "To examine whether acute dystonia is induced by neuroleptic treatment, common marmosets were treated with haloperidol orally twice a week over 25 weeks until dystonic behavior was elicited." | 3.69 | The common marmoset (Callithrix jacchus) as a model for neuroleptic-induced acute dystonia. ( Fukuoka, T; Kohda, A; Matsuo, M; Nakano, M; Okuno, Y, 1997) |
| "Measurement of plasma prolactin (PRL) concentration and plasma homovanillic acid (HVA) concentration was performed in 24 patients with schizophrenia during maintenance haloperidol treatment." | 3.68 | Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia. ( Csernansky, JG; Newcomer, JW; Riney, SJ; Vinogradov, S, 1992) |
| " But 2 days later he developed auditory hallucinations which were interpreted as alcohol hallucinations, for which he was additionally given haloperidol, 15 mg/d." | 3.68 | [Central anticholinergic intoxication syndrome. A contribution to the differential diagnosis of exogenous psychoses]. ( Eikmeier, G; Gastpar, M; Kastrup, O, 1991) |
| "After cessation of long-term treatment with haloperidol, a 77-year-old man developed severe dyskinetic-dystonic movements involving mainly the tongue and associated also with oromandibular dystonia and blepharospasm that were manifested exclusively during the process of eating and that interfered with feeding." | 3.68 | Tardive eating dystonia. ( Achiron, A; Melamed, E, 1990) |
| " To investigate further the issue the effects of alloxan-induced hyperglycemia on the incidence and severity of haloperidol-induced perioral movements were studied in the rat." | 3.68 | Increased incidence of neuroleptic-induced perioral movements in the rat by hyperglycemia. ( Sandyk, R, 1990) |
| " Oscillations in forelimb force during this performance were spectrally analyzed to describe the tremorogenic effects of haloperidol (0." | 3.68 | A new rodent model for neuroleptic-induced pseudo-parkinsonism: low doses of haloperidol increase forelimb tremor in the rat. ( Fowler, SC; Liao, RM; Skjoldager, P, 1990) |
| " We present the first case of WES in an infant born to a mother taking haloperidol during her pregnancy." | 3.67 | Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy. ( Barak, Y; Sexson, WR, 1989) |
| "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia." | 3.66 | New data on lithium and haloperidol incompatibility. ( Frankel, M; Spring, G, 1981) |
| " Over a 24 hour period, the following symptoms could be observed: akathisia, circling, akinesia, choreoathetoid and dystonic movements, oro-facial dyskinesias and postural tremor with or without harmaline." | 3.65 | Haloperidol-induced dyskinesias in the monkey. ( Bédard, P; Delean, J; Lafleur, J; Larochelle, L, 1977) |
| "Three patients, aged 23-33 years, with the diagnosis of schizophrenia, developed symptoms of tardive dyskinesia while receiving neuroleptic treatment, mostly with haloperidol." | 3.65 | Diazepam in the treatment of tardive dyskinesia. Preliminary observations. ( Singh, MM, 1976) |
| "Risperidone was shown to have significant anti-manic effects which was observed as early as week 1, following start of treatment." | 2.77 | Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania. ( Hsu, MC; Kuo, CC; Ouyang, WC; Yeh, IN, 2012) |
| "Risperidone was hypothesized to have better extrapyramidal tolerability and efficacy in treating negative symptoms." | 2.73 | Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. ( Braus, DF; Buchkremer, G; Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klosterkötter, J; Kühn, KU; Maier, W; Möller, HJ; Ohmann, C; Riedel, M; Riesbeck, M; Schlösser, R; Schneider, F; Wickelmaier, F, 2008) |
| "Ziprasidone induces lower D2 RO and EPS than haloperidol, which is consistent with an atypical antipsychotic profile." | 2.71 | Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. ( Aguilar, Y; Alvarez, E; Carrió, I; Catafau, AM; Corripio, I; Mena, E; Perez, V; Puigdemont, D, 2005) |
| "Haloperidol was associated with a sustained hyperprolactinemia, unlike ziprasidone, where only transient elevations in prolactin that returned to normal within the dosing interval were observed." | 2.69 | An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. ( Goff, DC; Herz, L; Kletti, N; Ko, GN; Lapierre, K; Law, CG; Posever, T; Simmons, J; Wilner, KD, 1998) |
| "Risperidone (6 to 16 mg)-treated patients showed significantly (p < 0." | 2.68 | Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. ( Chouinard, G, 1995) |
| "During long-term treatment of schizophrenia with antipsychotic medication, side effects such as weight gain and tardive dyskinesia may develop, while other extrapyramidal side effects may continue." | 2.67 | Side effects during long-term treatment with depot antipsychotic medication. ( Cookson, JC, 1991) |
| "Haloperidol treated patients reported more tiredness and drowsiness than remoxipride treated patients." | 2.67 | A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. ( Beckmann, H; Bunse, J; Dittmann, V; Klieser, E; König, P; Laux, G; Schöny, HW; Schröder, HG; Schubert, H; Unterweger, B, 1990) |
| " The dosage equivalency of haloperidol decanoate (1." | 2.66 | A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. ( Annable, L; Campbell, W; Chouinard, G, 1989) |
| "Haloperidol treatment masked withdrawal-exacerbated tardive dyskinesia more than molindone did; this difference (measured by percent change in AIMS scores) was significant (p = ." | 2.66 | Molindone and haloperidol in tardive dyskinesia. ( Benarroche, CL; Glazer, WM; Hafez, HM, 1985) |
| "Clonazepam was found to be significantly more efficacious than lithium in reducing manic symptoms despite the fact that during clonazepam treatment less patients required PRNs of haloperidol." | 2.65 | Antimanic effect of clonazepam. ( Annable, L; Chouinard, G; Young, SN, 1983) |
| " Overall, 25 years of experience have indicated that haloperidol can be used safely and effectively to manage a variety of psychiatric illnesses, so long as dosage and method of administration are adjusted to individual patients' needs." | 2.65 | Haloperidol: a quarter century of experience. ( Ayd, FJ; Settle, EC, 1983) |
| "01) 6 hours after dosing by metoclopramide 40 mg, and haloperidol 5 mg and 10 mg, when compared to placebo." | 2.65 | Metoclopramide and haloperidol in tardive dyskinesia. ( Bateman, DN; Dutta, DK; McClelland, HA; Rawlins, MD, 1979) |
| "Aripiprazole is an effective treatment for mania in a population that includes adults, children and adolescents, although its use leads to gastrointestinal disturbances and movement disorders." | 2.49 | Aripiprazole alone or in combination for acute mania. ( Brown, R; Geddes, J; Taylor, MJ, 2013) |
| "Most traditional neuroleptics have a narrow therapeutic-to-toxic index, and thus, the novel antipsychotics are the result of a search to substantially widen the distance between the dose that treats psychosis and the one that produces adverse effects." | 2.40 | The relationship of pharmacology to side effects. ( Casey, DE, 1997) |
| "Risperidone has these pharmacologic properties." | 2.39 | Extrapyramidal side effects and tolerability of risperidone: a review. ( Owens, DG, 1994) |
| "Mice treated with haloperidol develop many of the features of TD, including jaw tremors, tongue protrusions, and vacuous chewing movements (VCMs)." | 1.56 | Antipsychotic Behavioral Phenotypes in the Mouse Collaborative Cross Recombinant Inbred Inter-Crosses (RIX). ( Crowley, JJ; DeCristo, DM; Giusti-Rodríguez, P; Manuel de Villena, FP; Miller, DR; Nonneman, RJ; Quackenbush, CR; Ryan, A; Shaw, GD; Sullivan, PF; Xenakis, JG; Zhabotynsky, V; Zou, F, 2020) |
| "Haloperidol (1 mg/kg, ip) was administered for 21 successive days to induce orofacial dyskinesia and catalepsy." | 1.48 | Protective effect of hesperetin against haloperidol-induced orofacial dyskinesia and catalepsy in rats. ( Dhingra, D; Gahalain, N; Goswami, S, 2018) |
| "Mice treated with haloperidol showed an increase in microglial activation and inflammatory mediators in the striatum." | 1.48 | Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors. ( Cunha, TM; Del Bel, EA; Guimarães, FS; Prado, DS; Raisman-Vozari, R; Sepulveda-Diaz, JE; Sonego, AB; Tirapelli, CR; Vale, GT, 2018) |
| "Tardive dyskinesia (TD) is a serious side effect of long-term administration of typical neuroleptics, such as haloperidol." | 1.43 | Ginkgo biloba leaf extract and alpha-tocopherol attenuate haloperidol-induced orofacial dyskinesia in rats: Possible implication of antiapoptotic mechanisms by preventing Bcl-2 decrease and Bax elevation. ( An, HM; Lv, MH; Shi, J; Soares, JC; Tan, YL; Wang, Z; Yang, F; Zhang, XY; Zhou, D, 2016) |
| " To test this hypothesis in a rodent model, the A2A receptor antagonists SCH 412348 (3 mg/kg), vipadenant (10 mg/kg), caffeine (30 mg/kg), or istradefylline (3 mg/kg) were chronically (19-22 days) administered to Sprague Dawley rats, and dyskinetic behaviors were scored across this chronic dosing paradigm." | 1.39 | A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats. ( Bleickardt, C; Hodgson, R; Jones, N; Mullins, D; Parker, E, 2013) |
| "Both haloperidol and nicotine treatment decreased the transporter and α6β2* nAChRs (the asterisk indicates the possible presence of other nicotinic subunits in the receptor complex) when given alone, with no further decline with combined drug treatment." | 1.38 | Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats. ( Bordia, T; McIntosh, JM; Quik, M, 2012) |
| " Despite its satisfactory therapeutic effect, its chronic use is related to severe motor side effects." | 1.38 | Haloperidol-loaded polysorbate-coated polymeric nanocapsules decrease its adverse motor side effects and oxidative stress markers in rats. ( Barcelos, RC; Beck, RC; Benvegnú, DM; Boufleur, N; Bürger, ME; da Silva, Cde B; Flores, FC; Nora, MD; Ourique, AF; Pase, CS; Reckziegel, P, 2012) |
| "Haloperidol decanoate was injected to a thigh muscle once every four weeks for 18 weeks." | 1.38 | Ameliorative effect of yokukansan on vacuous chewing movement in haloperidol-induced rat tardive dyskinesia model and involvement of glutamatergic system. ( Ikarashi, Y; Kanno, H; Kase, Y; Sekiguchi, K; Yamaguchi, T, 2012) |
| "Haloperidol is an antipsychotic drug associated with the development of movement disorders." | 1.37 | Haloperidol-loaded polysorbate-coated polymeric nanocapsules increase its efficacy in the antipsychotic treatment in rats. ( Barcelos, RC; Beck, RC; Benvegnú, DM; Boufleur, N; Bürger, ME; Ourique, AF; Pase, CS; Reckziegel, P, 2011) |
| "Rats treated with haloperidol at doses of 0." | 1.37 | Reversal of haloperidol-induced motor deficits by mianserin and mesulergine in rats. ( Haleem, DJ; Shireen, E, 2011) |
| "Haloperidol (HP) is a widely prescribed antipsychotic drug used for the treatment of mental disorders." | 1.37 | Alpha-phenyl-N-tert-butylnitrone prevents oxidative stress in a haloperidol-induced animal model of tardive dyskinesia: investigating the behavioural and biochemical changes. ( Daya, RP; Mishra, RK; Skoblenick, K; Sookram, CD; Tan, ML, 2011) |
| "3 mg/kg) produced a transient decrease of extracellular DA levels over 6 h and showed maximum PPX levels 2 h after dosing which decreased over the following 6-8 h." | 1.36 | Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats. ( Buck, K; Buerger, E; Ferger, B; Koros, E; Shimasaki, M; Voehringer, P, 2010) |
| "Blonanserin is a novel antipsychotic agent that preferentially interacts with dopamine D(2) and 5-HT(2A) receptors." | 1.36 | Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist. ( Imaki, J; Ohno, Y; Okano, M; Okumura, T; Shimizu, S; Tatara, A, 2010) |
| " Chronic administration of haloperidol (1 mg/kg i." | 1.35 | Co-administration of nitric oxide (NO) donors prevents haloperidol-induced orofacial dyskinesia, oxidative damage and change in striatal dopamine levels. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2009) |
| "Haloperidol patients were more often single and institutionalised, less educated, had more residual schizophrenia, were longer hospitalised in the previous year, took more corrective and psychotropic drugs and had more extrapyramidal symptoms (EPS) and gynaecomastia (all significantly)." | 1.35 | Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. ( Albert, A; De Graeve, D; Gillain, B; Peuskens, J; Van Vleymen, B, 2009) |
| " This study was planned to investigate changes in striatal levels of norepinephrine, dopamine and serotonin after acute and chronic administration of classical neuroleptics (haloperidol and chlorpromazine)." | 1.35 | In vivo microdialysis studies of striatal level of neurotransmitters after haloperidol and chlorpromazine administration. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2009) |
| "Haloperidol (HAL) is a widely used neuroleptic drug for the treatment of acute and chronic psychosis." | 1.35 | Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats. ( Himabindhu, G; Thaakur, S, 2009) |
| "In the rat, akinetic catalepsy induced by a dopamine D2 receptor antagonist (haloperidol 5mg/kg) can model human catalepsy." | 1.35 | Righting elicited by novel or familiar auditory or vestibular stimulation in the haloperidol-treated rat: rat posturography as a model to study anticipatory motor control. ( Clark, CA; Sacrey, LA; Whishaw, IQ, 2009) |
| " Chronic administration of haloperidol (1 mg/kg, i." | 1.35 | Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2008) |
| "Pretreatment with curcumin reversed these behavioral changes." | 1.35 | Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2008) |
| "Rats treated with haloperidol at a dose of 1 mg/kg exhibited impaired motor coordination and a decrease in exploratory activity." | 1.34 | Reversal of haloperidol-induced extrapyramidal symptoms by buspirone: a time-related study. ( Haleem, DJ; Haleem, MA; Samad, N, 2007) |
| " The present study compares the effect of chronic administration of typical and atypical antipsychotics on neurochemical profile in rat forebrain." | 1.34 | Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia. ( Bishnoi, M; Chopra, K; Kulkarni, SK; Kumar, A, 2007) |
| " Chronic administration of haloperidol (1 mg/kg, i." | 1.34 | Protective effect of adenosine reuptake inhibitors in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2007) |
| "Haloperidol (HAL) is a typical antipsychotic drug and known to cause extrapyramidal symptoms (EPS) that may be associated with the blockade of dopamine D2-receptors in nigrostriatal pathway by the drug." | 1.34 | Quetiapine reverses altered locomotor activity and tyrosine hydroxylase immunoreactivity in rat caudate putamen following long-term haloperidol treatment. ( He, J; Jiang, W; Li, X; Li, XM; Xu, H; Yan, B; Zhang, Y, 2007) |
| "Rats treated with haloperidol at a dose of 1 mg/kg twice a day for 2 weeks displayed VCMs with twitching of facial musculature that increased in a time dependent manner as the treatment continued to 5 weeks." | 1.34 | Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats. ( Haleem, DJ; Haleem, MA; Samad, N, 2007) |
| " Chronic administration of haloperidol (1 mg/kg) and chlorpromazine (5 mg/kg) resulted in a time-dependent increase in orofacial hyperkinetic movements." | 1.34 | Neurochemical changes associated with chronic administration of typical antipsychotics and its relationship with tardive dyskinesia. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2007) |
| "Treatment with haloperidol increases oxyradicals which are implicated in TD." | 1.34 | Effect of spirulina maxima on the haloperidol induced tardive dyskinesia and oxidative stress in rats. ( Jyothi, B; Thaakur, SR, 2007) |
| "Present study was designed to monitor the responsiveness of 5HT (5-Hydroxytryptamine) -2C receptors following the long-term administration of haloperidol in rats." | 1.34 | Neurochemical and behavioral effects of m-CPP in a rat model of tardive dyskinesia. ( Haleem, DJ; Ikram, H; Samad, N, 2007) |
| "Risperidone is a second-generation antipsychotic that lacks acute motor side effects at low doses (<6 mg/day), but above this level is associated with parkinsonism and akathesia." | 1.33 | Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia. ( Cooper, T; Gao, XM; Suckow, RF; Tamminga, CA, 2006) |
| "Risperidone-treated animals showed a catalepsy-like phenotype, which differed to that of haloperidol-treated rats, indicating that processes other than the anticipated dopaminergic mechanisms are underlying this phenomenon." | 1.33 | Behavioural effects of chronic haloperidol and risperidone treatment in rats. ( Dedova, I; Duffy, L; Karl, T; Matsumoto, I; O'brien, E, 2006) |
| "A dose-response relationship between dopamine D(2) occupancy and acute extrapyramidal symptoms (EPS) has been well established." | 1.32 | The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. ( Kapur, S; Nobrega, JN; Remington, G; Turrone, P, 2003) |
| "Quercetin is a bioflavonoid with strong antioxidant properties." | 1.32 | Reversal of haloperidol-induced orofacial dyskinesia by quercetin, a bioflavonoid. ( Kulkarni, SK; Naidu, PS; Singh, A, 2003) |
| "Similarly to acute rat catalepsy, "early onset" vacuous chewing movements (VCMs) induced by subchronic treatment with antipsychotic have recently been proposed as a model of human extrapyramidal symptoms." | 1.32 | Haloperidol versus risperidone on rat "early onset" vacuous chewing. ( Bartholini, F; Casti, P; Casu, MA; Congeddu, E; Marchese, G; Pani, L; Ruiu, S; Tambaro, S, 2004) |
| "Haloperidol (HP) has been hypothesized to potentiate increases in oxidative stress or free radical-mediated levels of toxic metabolites in rat striatum while simultaneous upregulating dopamine (DA)-D2 receptors leading to presumed DA supersensitivity." | 1.32 | Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia. ( Fairfax, DF; Gupta, SK; Henry, P; Khan, RF; Mishra, RK; N-Marandi, S; Rogoza, RM, 2004) |
| "Furthermore, catalepsy was also tested after administration of each of these drugs." | 1.31 | Discrimination of morphine- and haloperidol-induced muscular rigidity and akinesia/catalepsy in simple tests in rats. ( Ferger, B; Fischer, DA; Kuschinsky, K, 2002) |
| "With the background of a number of meta-analyses on the optimal neuroleptic dosages [1,2] the average daily dosage for the treatment of acute schizophrenic episodes recommended in the internal treatment guidelines of our psychiatric clinic was reduced from 24 mg to 15 mg haloperidol equivalent." | 1.31 | ["More is less": a retrospective study of haloperidol dosages in acute schizophrenia]. ( Kissling, W; Kockott, G; Müller, R, 2000) |
| "Haloperidol treatment produced a significant reduction in mu-receptor binding in the globus pallidus (P<0." | 1.31 | Decreased mu-opioid receptor binding in the globus pallidus of rats treated with chronic haloperidol. ( Baca, SM; Bower, CM; Egan, MF; Hamid, EH; Hyde, TM; Zaka, M, 2000) |
| "Haloperidol was administered for 20 weeks, and rats with high and low levels of vacuous chewing movements (VCM) were analyzed for morphological changes with electron microscopy at three time points." | 1.31 | Oral dyskinesias and morphological changes in rat striatum during long-term haloperidol administration. ( Andreassen, OA; Jørgensen, HA; Meshul, CK; Moore, C, 2001) |
| "The muscle rigidity was measured as an increased resistance of a hind leg to passive extension and flexion at the ankle joint." | 1.31 | Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. ( Konieczny, J; Ossowska, K; Pilc, A; Wierońska, J; Wolfarth, S, 2001) |
| "Catalepsy was induced in rats by acute treatment with haloperidol (1 mg/kg), and catalepsy was scored for the next 4 h." | 1.31 | Possible involvement of prostaglandins in haloperidol-induced orofacial dyskinesia in rats. ( Kulkarni, SK; Naidu, PS, 2001) |
| " Both acute and chronic administration of seganserin, ketanserin and ritanserin, 5-HT2A/2C receptor antagonists, also reduced haloperidol-induced vacuous chewing movements in a dose-dependent (0." | 1.31 | Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements. ( Kulkarni, SK; Naidu, PS, 2001) |
| "The possibility that chronic administration of haloperidol could induce cumulative neuronal loss in the substantia nigra pars reticulata and thereby induce the pathological changes which lead to tardive dyskinesia is discussed." | 1.31 | Acute administration of haloperidol induces apoptosis of neurones in the striatum and substantia nigra in the rat. ( Cooper, AC; Cooper, AJ; Griffiths, MR; Mitchell, IJ, 2002) |
| "Haloperidol-induced TD was also attenuated by the antioxidant, vitamin E (400 and 800 mg/kg, p." | 1.31 | Effect of Withania somnifera glycowithanolides on a rat model of tardive dyskinesia. ( Bhattacharya, D; Bhattacharya, SK; Ghosal, S; Sairam, K, 2002) |
| "All haloperidol-treated rats developed oral dyskinesias at a significantly higher rate than rats treated with water (p = 0." | 1.30 | The dose-response characteristics of rat oral dyskinesias with chronic haloperidol or clozapine administration. ( Cooper, TB; Gao, XM; Hashimoto, T; Tamminga, CA, 1997) |
| "Subjects were children with autism requiring pharmacotherapy for target symptoms." | 1.30 | Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. ( Adams, PB; Armenteros, JL; Campbell, M; Eisenberg, ZW; Malone, RP; Overall, JE, 1997) |
| " In addition, the polymorphic distribution of RH/HL ratios, suggested by previous investigators, was further tested in each dosage group (for controlling the potential dosage effect on RH/HL ratios)." | 1.30 | Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables. ( Chang, WH; Chang, YC; Hu, OY; Hu, WH; Jann, MW; Lane, HY; Lin, HN, 1997) |
| "This research explored the effects of haloperidol (HP) metabolites on biogenic amine uptake and release, and compared them to those of MPTP and its toxic metabolite, MPP+." | 1.30 | Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia. ( Barlow, RL; Bempong, J; Bloomquist, JR; Kirby, ML; Wright, AM, 1998) |
| "Dopa-responsive dystonia, an autosomal-dominant disorder caused by mutations in the guanosine triphosphate (GTP)-cyclohydrolase I gene, is characterized by severe striatal dopamine depletion." | 1.30 | Tardive dyskinesia in dopa-responsive dystonia: a reappraisal of the dopamine hypothesis of tardive dyskinesia. ( de la Fuente-Fernández, R, 1998) |
| "It has been hypothesized that free radicals play a causative role in tardive dyskinesia, which is an inveterate movement disorder caused by chronic administration of neuroleptics." | 1.30 | In vivo analysis of hydrogen peroxide and lipid radicals in the striatum of rats under long-term administration of a neuroleptic. ( Kamada, H; Kasai, N; Konaka, R; Matsue, T; Mori, N; Niwa, R; Ohya-Nishiguchi, H; Tsuchihashi, N; Ueda, Y; Yokoyama, H, 1998) |
| "Haloperidol-treated rats displayed a significant emergence of NMDA stimulated oral activity (nondirected oral movements, oral tremor, audible teeth grinding, and directed oral movements)." | 1.30 | Emergence of oral and locomotor activity in chronic haloperidol-treated rats following cortical N-methyl-D-aspartate stimulation. ( Grimm, JW; Kruzich, PJ; See, RE, 1998) |
| " After chronic haloperidol dosing (vehicle, 0." | 1.30 | Chronic haloperidol produces a time- and dose-related slowing of lick rhythm in rats: implications for rodent models of tardive dyskinesia and neuroleptic-induced parkinsonism. ( Fowler, SC; Wang, G, 1998) |
| " Here we report results of the association of oral chewing movements in rats with chronic administration of two new antipsychotic drugs, olanzapine and sertindole." | 1.30 | Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol. ( Gao, XM; Sakai, K; Tamminga, CA, 1998) |
| "The delirium was reversible when all drugs were stopped; however, dyskinesia was found to be persistent after a period of 6 months." | 1.30 | Delirium and persistent dyskinesia induced by a lithium-neuroleptic interaction. ( Berger, M; Brandt, C; Normann, C; Walden, J, 1998) |
| "The objective of this study was to examine neuroleptic effectiveness among Asians and Caucasians, and to investigate inter-ethnic pharmacodynamic differences." | 1.30 | An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol. ( Bean, G; Beiser, M; Zhang-Wong, J; Zipursky, RB, 1998) |
| "Haloperidol treatment for 34 weeks increased the optical density of preproenkephalin messenger RNA in individual striatal neurons and enkephalin peptide in the neuropil, regardless of the level of oral dyskinesia produced." | 1.30 | The relationship between oral dyskinesias produced by long-term haloperidol treatment, the density of striatal preproenkephalin messenger RNA and enkephalin peptide, and the number of striatal neurons expressing preproenkephalin messenger RNA in rats. ( Andreassen, OA; Finsen, B; Jørgensen, HA; Ostergaard, K; Sørensen, JC; West, MJ, 1999) |
| "Haloperidol treatment significantly increased dyskinetic movements and striatal dopamine D2 receptor density compared with controls." | 1.29 | Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol. ( Fukui, S; Hashimoto, K; Inada, T; Iyo, M; Sasaki, H, 1995) |
| "However, the severity of the catalepsy score following the third through seventh injections of haloperidol strongly correlated with the concurrent number of VCMs." | 1.29 | Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate. ( Egan, MF; Hyde, TM; Kleinman, JE; Weinberger, DR; Wing, LL; Wyatt, RJ, 1995) |
| " To the extent that the VCM syndrome models TD, the absence of long-term suppression of the VCM syndrome suggests that, at this dosage range, increasing depot neuroleptic doses may not be a useful long-term strategy for TD suppression." | 1.29 | Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose. ( Egan, MF; Hyde, TM; Kleinman, JE; Wyatt, RJ, 1995) |
| "Acute and chronic administration of vigabatrin, a selective inactivator of GABA-T, suppresses haloperidol-induced dyskinesias at low doses without preventing the enhancement of striatal dopamine D2 receptor density or the development of vacuous chewing movements." | 1.29 | Suppression of haloperidol-induced oral dyskinesias in rats by vigabatrin. ( Elands, J; Gobaille, S; Grauffel, C; Knödgen, B; Moran, P; Sarhan, S; Seiler, N; van den Buuse, M, 1995) |
| "This haloperidol treatment also induced a significantly increase in the frequency of involuntary chewing movements and tongue protrusions, which are considered as a model of tardive dyskinesia." | 1.29 | Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats. ( Fukui, S; Hashimoto, K; Inada, T; Iyo, M; Kitao, Y; Maeda, Y; Sasaki, H, 1995) |
| "In the catalepsy test, felbamate antagonized dopamine D2 receptor- but not D1 receptor-induced akinesia." | 1.29 | Felbamate, an anti-convulsive drug, has anti-parkinsonian potential in rats. ( Kretschmer, BD, 1994) |
| "Chronic administration of haloperidol to male Sprague Dawley rats for 6 months at a dosage of 1." | 1.29 | Tiagabine inhibits haloperidol-induced oral dyskinesias in rats. ( Friedman, MB; Gao, XM; Kakigi, T; Tamminga, CA, 1994) |
| "Neither (-)-3-PPP nor SND 919 produced dystonia, but had observable dopamine D2 receptor agonistic effects, (-)-3-PPP producing emesis at 1-4 mg/kg and SND 919 producing motoric unrest and stereotypy at 0." | 1.29 | Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol. ( Gerlach, J; Peacock, L, 1993) |
| "Naloxone treatment had little effect on VCMs but increased catalepsy scores in both haloperidol and vehicle treated groups." | 1.29 | Effects of chronic naloxone administration on vacuous chewing movements and catalepsy in rats treated with long-term haloperidol decanoate. ( Egan, MF; Ferguson, JN; Hyde, TM, 1995) |
| "Elderly women with depression are at risk even on a low dosis." | 1.29 | [Tardive dyskinesia: an increased risk of neuroleptics in elderly women]. ( Jessurun, AY; Stek, ML, 1995) |
| "Haloperidol-induced VC were inhibited by the s." | 1.28 | Haloperidol-induced vacuous chewing in rats: suppression by alpha-methyl-tyrosine. ( Collu, M; Diana, M; Gessa, GL; Mura, A, 1992) |
| "Haloperidol was implicated in 47 patients (37%), followed by amitriptyline/perphenazine in 30%, thioridazine in 27%, and chlorpromazine in 20%." | 1.28 | Neurologic approach to drug-induced movement disorders: a study of 125 patients. ( Jankovic, J; Miller, LG, 1990) |
| " These data suggest that persisting alterations in receptor binding are primarily seen in dopamine D2 and GABA receptors after withdrawal from chronic administration of haloperidol but not the atypical neuroleptics, clozapine and raclopride." | 1.28 | Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats. ( Ellison, G; See, RE; Toga, AW, 1990) |
| "Treatment with haloperidol (0." | 1.28 | Drug-induced purposeless chewing: animal model of dyskinesia or nausea? ( Iversen, SD; Rupniak, NM; Tye, SJ, 1990) |
| " Long-term administration induced distinctively different patterns of oral activity in the three drug groups, both in number of CSMs and the form of these movements." | 1.28 | Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia. ( Ellison, G; See, RE, 1990) |
| " The authors examined the possibilities of a pharmacokinetic effect of alprazolam on neuroleptic plasma levels and of a clinical effect of alprazolam." | 1.28 | Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates. ( Angrist, B; Cooper, T; Douyon, R; Peselow, E; Rotrosen, J, 1989) |
| " This phenomenon, probably due to the inhibition of the striato-nigral GABA-ergic pathway, could serve as an easy and reliable model for the human tardive dyskinesias dues to the chronic administration of neuroleptics." | 1.28 | [Oral dyskinesia in rats after a single administration of haloperidol combined with GABA-linoleamide. A model of dyskinesia in man]. ( Vamvakides, A, 1989) |
| "A positive FH-NIDDM was significantly associated with the presence of TD and with higher drug-free FBS." | 1.28 | Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance. ( Mukherjee, S; Roth, SD; Sandyk, R; Schnur, DB, 1989) |
| "The bromperidol serum values were not correlated with the therapeutic response but, at more than 5 ng per ml, there might be a positive correlation between the bromperidol levels and clinical efficacy in the newly admitted schizophrenics." | 1.27 | Clinical efficacy, extrapyramidal symptoms and serum levels: influence of administration schedules and concomitant drugs on serum bromperidol concentrations. ( Fujii, Y; Itoh, H; Kamisada, M; Nakajima, S; Takamiya, M; Tanoue, A; Tateyama, M, 1984) |
| "Treatment with molindone for 14 days at 3, 6, 20 and 40 mg/kg, enhanced the stereotyped behavioral response induced by apomorphine and increased the numbered of D-2 dopamine receptors in the striatum (Bmax) labelled by high affinity (Kd = 40 pmol) binding or [3H] spiroperidol in the guinea-pig." | 1.27 | Molindone compared to haloperidol in a guinea-pig model of tardive dyskinesia. ( Curtin, J; Fields, J; Koller, W, 1984) |
| " Evidence for this is based on the fact that in our patients and others mentioned in the literature the dosage and blood levels of lithium were not high." | 1.27 | Toxic irreversible encephalopathy induced by lithium carbonate and haloperidol. A report of 2 cases. ( Hurwitz, MD; Sandyk, R, 1983) |
| "Four Cebus apella monkeys with persistent dyskinetic movements induced by earlier long-term administration of haloperidol were subjected to a trial of the dyskinesia-modifying effects of a novel dopamine autoreceptor agonist 3-PPP (3[3-hydroxyphenyl]-N-n-propyl-piperidine)." | 1.27 | Antidyskinetic action of 3-PPP, a selective dopaminergic autoreceptor agonist, in Cebus monkeys with persistent neuroleptic-induced dyskinesias. ( Carlsson, A; Gunne, LM; Häggström, JE; Wikström, H, 1983) |
| "In ongoing studies of chronic administration of neuroleptics to monkeys (Cebus apella) and rats, the regional distribution of glutamic acid decarboxylase (GAD) and brain levels of homovanillic acid were examined." | 1.27 | Experimental tardive dyskinesia. ( Gunne, LM; Häggström, JE, 1985) |
| " Such variations have been attributed to individual metabolism, pharmacologic differences, and age--all of which may need careful consideration in prescribing an appropriate dosage regimen for a given patient." | 1.27 | Interpatient variations in antipsychotic therapy. ( Gershon, S; McIntyre, IM, 1985) |
| "Haloperidol was given first in doses of 1." | 1.27 | Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review. ( Domino, EF, 1985) |
| " Moreover pharmacokinetic data increasingly have been clinically applied." | 1.27 | Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations. ( Knudsen, P, 1985) |
| "Rats with ablated frontal sensorimotor cortex and one with ablated sensorimotor connections to forebrain showed more vacuous chewing movements following 6-week chronic administration of a neuroleptic than did occipitally damaged rats or normal controls who were treated in the same way." | 1.26 | Oral dyskinesia in brain-damaged rats withdrawn from a neuroleptic: implication for models of tardive dyskinesia. ( Glassman, HN; Glassman, RB, 1980) |
| "In recent years, the complex treatment of schizophrenia has been extended by the neuroleptic large-dose therapy." | 1.26 | [Neuroleptic large dose therapy of schizophrenias]. ( Pethö, B; Ungvári, G, 1981) |
| "A 7-year-old boy with multiple tic or Gilles de la Tourette's disease was treated with haloperidol." | 1.26 | Haloperidol-induced tardive dyskinesia in a child with Gilles de la Tourette's disease. ( Holtzman, D; Mizrahi, EM; Tharp, B, 1980) |
| "Attacks of acute dystonia have been noticed in all animals, sometimes necessitating anticholinergic medication or decreases in the daily haloperidol dose." | 1.26 | Development of acute dystonia and tardive dyskinesia in cebus monkeys. ( Bárány, S; Gunne, LM; Ingvast, A, 1979) |
| "We conclude that phenytoin induced hyperkinesias reflect a specific effect of phenytoin on an abnormal neural substrate and suggest the presence of an otherwise silent pathological alteration of the corpus striatum." | 1.26 | Clinical and experimental studies of phenytoin-induced hyperkinesias. ( Klawans, HL; Koller, WC; Nausieda, PA; Weiner, WJ, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 188 (33.63) | 18.7374 |
| 1990's | 165 (29.52) | 18.2507 |
| 2000's | 153 (27.37) | 29.6817 |
| 2010's | 52 (9.30) | 24.3611 |
| 2020's | 1 (0.18) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, H | 1 |
| He, X | 1 |
| Thurkauf, A | 1 |
| Hoffman, D | 1 |
| Kieltyka, A | 1 |
| Brodbeck, R | 1 |
| Primus, R | 1 |
| Wasley, JW | 1 |
| Giusti-Rodríguez, P | 1 |
| Xenakis, JG | 1 |
| Crowley, JJ | 1 |
| Nonneman, RJ | 1 |
| DeCristo, DM | 1 |
| Ryan, A | 1 |
| Quackenbush, CR | 1 |
| Miller, DR | 1 |
| Shaw, GD | 1 |
| Zhabotynsky, V | 1 |
| Sullivan, PF | 1 |
| Manuel de Villena, FP | 1 |
| Zou, F | 1 |
| Dhingra, D | 1 |
| Goswami, S | 1 |
| Gahalain, N | 1 |
| Lévesque, C | 1 |
| Hernandez, G | 1 |
| Mahmoudi, S | 1 |
| Calon, F | 1 |
| Gasparini, F | 1 |
| Gomez-Mancilla, B | 1 |
| Blanchet, PJ | 1 |
| Lévesque, D | 2 |
| Taraskina, AE | 1 |
| Nasyrova, RF | 1 |
| Zabotina, AM | 1 |
| Sosin, DN | 1 |
| Sosina, КА | 1 |
| Ershov, EE | 1 |
| Grunina, MN | 1 |
| Krupitsky, EM | 1 |
| El-Sayeh, HG | 1 |
| Rathbone, J | 1 |
| Soares-Weiser, K | 1 |
| Bergman, H | 1 |
| Sonego, AB | 1 |
| Prado, DS | 1 |
| Vale, GT | 1 |
| Sepulveda-Diaz, JE | 1 |
| Cunha, TM | 1 |
| Tirapelli, CR | 1 |
| Del Bel, EA | 1 |
| Raisman-Vozari, R | 1 |
| Guimarães, FS | 1 |
| Shireen, E | 2 |
| Naeem, S | 1 |
| Inam, QU | 1 |
| Haleem, DJ | 9 |
| Jones, N | 1 |
| Bleickardt, C | 1 |
| Mullins, D | 1 |
| Parker, E | 1 |
| Hodgson, R | 1 |
| An, HM | 2 |
| Tan, YL | 2 |
| Shi, J | 2 |
| Wang, ZR | 1 |
| Li, J | 1 |
| Wang, YC | 2 |
| Kosten, TR | 1 |
| Zhou, DF | 1 |
| Yang, FD | 1 |
| Zhang, XY | 2 |
| Hsu, CY | 1 |
| Lin, YH | 1 |
| Shen, YC | 1 |
| Brown, R | 1 |
| Taylor, MJ | 1 |
| Geddes, J | 1 |
| Konieczny, J | 2 |
| Lenda, T | 1 |
| Röpke, J | 1 |
| Busanello, A | 1 |
| Leal, CQ | 1 |
| de Moraes Reis, E | 1 |
| de Freitas, CM | 1 |
| Villarinho, JG | 1 |
| Figueira, FH | 1 |
| Mello, CF | 1 |
| Ferreira, J | 2 |
| Fachinetto, R | 4 |
| Lewitus, GM | 1 |
| Pribiag, H | 1 |
| Duseja, R | 1 |
| St-Hilaire, M | 1 |
| Stellwagen, D | 1 |
| Tardy, M | 1 |
| Huhn, M | 1 |
| Kissling, W | 2 |
| Engel, RR | 1 |
| Leucht, S | 2 |
| Samad, N | 6 |
| Dekundy, A | 1 |
| Mela, F | 2 |
| Hofmann, M | 1 |
| Danysz, W | 1 |
| Iderberg, H | 2 |
| Maslava, N | 1 |
| Thompson, AD | 1 |
| Bubser, M | 3 |
| Niswender, CM | 2 |
| Hopkins, CR | 1 |
| Lindsley, CW | 1 |
| Conn, PJ | 2 |
| Jones, CK | 2 |
| Cenci, MA | 2 |
| McCreary, AC | 1 |
| Varney, MA | 1 |
| Kleven, MS | 1 |
| Koek, W | 1 |
| Bardin, L | 1 |
| Depoortère, R | 1 |
| Newman-Tancredi, A | 1 |
| Digby, G | 1 |
| Jalini, S | 1 |
| Taylor, S | 1 |
| McConnell, GC | 1 |
| So, RQ | 1 |
| Grill, WM | 1 |
| Malik, T | 1 |
| Hasan, S | 1 |
| Pervez, S | 1 |
| Fatima, T | 1 |
| Wang, Z | 1 |
| Lv, MH | 1 |
| Soares, JC | 1 |
| Zhou, D | 1 |
| Yang, F | 1 |
| Rasmussen, SA | 1 |
| Rosebush, PI | 1 |
| Mazurek, MF | 1 |
| Bishnoi, M | 13 |
| Chopra, K | 12 |
| Kulkarni, SK | 21 |
| Dolzan, V | 1 |
| Serretti, A | 1 |
| Mandelli, L | 1 |
| Koprivsek, J | 1 |
| Kastelic, M | 1 |
| Plesnicar, BK | 1 |
| Varty, GB | 1 |
| Hodgson, RA | 1 |
| Pond, AJ | 1 |
| Grzelak, ME | 1 |
| Parker, EM | 1 |
| Hunter, JC | 1 |
| Haleem, MA | 3 |
| Peuskens, J | 1 |
| Gillain, B | 1 |
| De Graeve, D | 1 |
| Van Vleymen, B | 1 |
| Albert, A | 1 |
| Thaakur, S | 1 |
| Himabindhu, G | 1 |
| Rajarethinam, R | 1 |
| Dziuba, J | 1 |
| Manji, S | 1 |
| Pizzuti, A | 1 |
| Lachover, L | 1 |
| Keshavan, M | 1 |
| Clark, CA | 1 |
| Sacrey, LA | 1 |
| Whishaw, IQ | 2 |
| Barcelos, RC | 3 |
| Benvegnú, DM | 3 |
| Boufleur, N | 3 |
| Reckziegel, P | 3 |
| Müller, LG | 1 |
| Pase, C | 1 |
| Emanuelli, T | 1 |
| Bürger, ME | 7 |
| Brown, AR | 1 |
| Hu, B | 1 |
| Antle, MC | 1 |
| Teskey, GC | 1 |
| Lawson, WB | 1 |
| Herman, BK | 1 |
| Loebel, A | 1 |
| Lazariciu, I | 1 |
| Malik, M | 1 |
| Mabrouk, OS | 1 |
| Marti, M | 2 |
| Morari, M | 2 |
| Syu, A | 1 |
| Ishiguro, H | 1 |
| Inada, T | 4 |
| Horiuchi, Y | 1 |
| Tanaka, S | 1 |
| Ishikawa, M | 1 |
| Arai, M | 1 |
| Itokawa, M | 1 |
| Niizato, K | 1 |
| Iritani, S | 1 |
| Ozaki, N | 1 |
| Takahashi, M | 1 |
| Kakita, A | 1 |
| Takahashi, H | 1 |
| Nawa, H | 1 |
| Keino-Masu, K | 1 |
| Arikawa-Hirasawa, E | 1 |
| Arinami, T | 1 |
| Sekhar, S | 1 |
| Kalra, B | 1 |
| Mendhekar, DN | 2 |
| Tekur, U | 1 |
| Ferger, B | 2 |
| Buck, K | 1 |
| Shimasaki, M | 1 |
| Koros, E | 1 |
| Voehringer, P | 1 |
| Buerger, E | 1 |
| Mishra, CB | 1 |
| Barodia, SK | 1 |
| Prakash, A | 1 |
| Senthil Kumar, JB | 1 |
| Luthra, PM | 1 |
| Pekkan, G | 1 |
| Kilicoglu, A | 1 |
| Algin, DI | 1 |
| Ohno, Y | 2 |
| Okano, M | 1 |
| Imaki, J | 1 |
| Tatara, A | 1 |
| Okumura, T | 1 |
| Shimizu, S | 1 |
| Nade, VS | 1 |
| Kawale, LA | 1 |
| Yadav, AV | 1 |
| Kane, JM | 3 |
| Potkin, SG | 1 |
| Daniel, DG | 3 |
| Buckley, PF | 1 |
| Bateup, HS | 1 |
| Santini, E | 1 |
| Shen, W | 1 |
| Birnbaum, S | 1 |
| Valjent, E | 1 |
| Surmeier, DJ | 1 |
| Fisone, G | 1 |
| Nestler, EJ | 1 |
| Greengard, P | 1 |
| Xue, Y | 1 |
| Chen, L | 1 |
| Pase, CS | 2 |
| Ourique, AF | 2 |
| Beck, RC | 2 |
| Sookram, C | 1 |
| Tan, M | 1 |
| Daya, R | 1 |
| Heffernan, S | 1 |
| Mishra, RK | 4 |
| Creed-Carson, M | 1 |
| Oraha, A | 1 |
| Nobrega, JN | 6 |
| Crespo-Facorro, B | 1 |
| Pérez-Iglesias, R | 1 |
| Mata, I | 1 |
| Ramirez-Bonilla, M | 1 |
| Martínez-Garcia, O | 1 |
| Pardo-Garcia, G | 1 |
| Caseiro, O | 1 |
| Pelayo-Terán, JM | 1 |
| Vázquez-Barquero, JL | 1 |
| Young, CK | 1 |
| Bland, BH | 1 |
| Daya, RP | 1 |
| Tan, ML | 1 |
| Sookram, CD | 1 |
| Skoblenick, K | 1 |
| Macêdo, DS | 1 |
| Oliveira, GV | 1 |
| Gomes, PX | 1 |
| Araújo, FY | 1 |
| Souza, CM | 1 |
| Vasconcelos, SM | 1 |
| Viana, GS | 1 |
| Sousa, FC | 1 |
| Carvalho, AF | 1 |
| Collins, LE | 1 |
| Sager, TN | 1 |
| Sams, AG | 1 |
| Pennarola, A | 1 |
| Port, RG | 1 |
| Shahriari, M | 1 |
| Salamone, JD | 1 |
| Patil, R | 1 |
| Hiray, Y | 1 |
| Shinde, S | 1 |
| Langade, P | 1 |
| Bordia, T | 1 |
| McIntosh, JM | 1 |
| Quik, M | 1 |
| Boparai, RK | 1 |
| Ouyang, WC | 1 |
| Hsu, MC | 1 |
| Yeh, IN | 1 |
| Kuo, CC | 1 |
| Bennouar, KE | 1 |
| Uberti, MA | 1 |
| Melon, C | 1 |
| Bacolod, MD | 1 |
| Jimenez, HN | 1 |
| Cajina, M | 1 |
| Kerkerian-Le Goff, L | 1 |
| Doller, D | 1 |
| Gubellini, P | 1 |
| Johnson, KA | 1 |
| Tantawy, MN | 1 |
| Marvanova, M | 1 |
| Ansari, MS | 1 |
| Baldwin, RM | 1 |
| Flores, FC | 1 |
| Nora, MD | 1 |
| da Silva, Cde B | 1 |
| Sekiguchi, K | 1 |
| Kanno, H | 1 |
| Yamaguchi, T | 1 |
| Ikarashi, Y | 1 |
| Kase, Y | 1 |
| Roberts, RC | 6 |
| Force, M | 1 |
| Kung, L | 1 |
| Fischer, DA | 1 |
| Kuschinsky, K | 1 |
| Truöl, S | 1 |
| Von Hippel, C | 1 |
| Raape, J | 1 |
| König, F | 1 |
| Ohye, C | 1 |
| Shibazaki, T | 1 |
| Turrone, P | 3 |
| Remington, G | 4 |
| Kapur, S | 3 |
| Naidu, PS | 9 |
| Singh, A | 6 |
| Kaur, P | 1 |
| Sandhir, R | 1 |
| de Graaf, L | 1 |
| Admiraal, P | 1 |
| van Puijenbroek, EP | 1 |
| Bhattachary, SK | 1 |
| Bhattacharya, D | 2 |
| Muruganandam, AV | 1 |
| Miller, DD | 2 |
| Koch, HJ | 1 |
| Szecsey, A | 1 |
| Vogel, M | 1 |
| Fischer-Barnicol, D | 1 |
| Sharma, S | 1 |
| Paladino, P | 1 |
| Gabriele, J | 1 |
| Saeedi, H | 1 |
| Henry, P | 2 |
| Chang, M | 1 |
| Johnson, RL | 1 |
| Gothelf, D | 1 |
| Apter, A | 1 |
| Reidman, J | 1 |
| Brand-Gothelf, A | 1 |
| Bloch, Y | 1 |
| Gal, G | 1 |
| Kikinzon, L | 1 |
| Tyano, S | 1 |
| Weizman, R | 1 |
| Ratzoni, G | 1 |
| Carvalho, RC | 1 |
| Silva, RH | 1 |
| Abílio, VC | 1 |
| Barbosa, PN | 1 |
| Frussa-Filho, R | 2 |
| Nel, A | 2 |
| Harvey, BH | 4 |
| Collier, DA | 1 |
| De Souza, IE | 2 |
| Dawson, NM | 2 |
| Clifford, JJ | 1 |
| Waddington, JL | 4 |
| Meredith, GE | 4 |
| Lapidus, B | 1 |
| McCullumsmith, RE | 1 |
| Stincic, TL | 1 |
| Agrawal, SM | 1 |
| Meador-Woodruff, JH | 1 |
| Sacchetti, E | 1 |
| Valsecchi, P | 1 |
| Apiquian, R | 1 |
| Fresán, A | 1 |
| Herrera, K | 1 |
| Ulloa, RE | 1 |
| Lóyzaga, C | 1 |
| de la Fuente-Sandoval, C | 1 |
| Gutiérrez, D | 1 |
| Nicolini, H | 1 |
| Collins, KO | 1 |
| Comer, JB | 1 |
| Andreassen, OA | 12 |
| Ferrante, RJ | 2 |
| Aamo, TO | 1 |
| Beal, MF | 2 |
| Jørgensen, HA | 12 |
| Oosthuizen, PP | 2 |
| Emsley, RA | 1 |
| Maritz, JS | 1 |
| Turner, JA | 1 |
| Keyter, N | 2 |
| Waage, J | 1 |
| Finsen, B | 4 |
| Switzer, RC | 1 |
| Napier, TC | 1 |
| Marchese, G | 3 |
| Bartholini, F | 3 |
| Ruiu, S | 3 |
| Casti, P | 2 |
| Casu, GL | 1 |
| Pani, L | 3 |
| Casu, MA | 2 |
| Congeddu, E | 1 |
| Tambaro, S | 1 |
| Correll, CU | 1 |
| Oosthuizen, P | 1 |
| Emsley, R | 4 |
| Jadri Turner, H | 1 |
| Shoham, S | 1 |
| Mazeh, H | 1 |
| Javitt, DC | 1 |
| Heresco-Levy, U | 1 |
| Dossenbach, M | 1 |
| Erol, A | 1 |
| el Mahfoud Kessaci, M | 1 |
| Shaheen, MO | 1 |
| Sunbol, MM | 1 |
| Boland, J | 1 |
| Hodge, A | 1 |
| O'Halloran, RA | 1 |
| Bitter, I | 1 |
| Turner, HJ | 1 |
| Schronen, J | 1 |
| Botha, K | 1 |
| Smit, R | 1 |
| Kelley, JJ | 2 |
| Matsumoto, C | 1 |
| Shinkai, T | 1 |
| Hori, H | 1 |
| Ohmori, O | 1 |
| Nakamura, J | 1 |
| Coppola, G | 1 |
| Morelli, E | 1 |
| Bravaccio, C | 1 |
| Federico, R | 1 |
| Gritti, A | 1 |
| Ethier, I | 1 |
| Kagechika, H | 1 |
| Shudo, K | 1 |
| Rouillard, C | 1 |
| Rogoza, RM | 1 |
| Fairfax, DF | 1 |
| N-Marandi, S | 1 |
| Khan, RF | 1 |
| Gupta, SK | 1 |
| Jackson, MJ | 1 |
| Al-Barghouthy, G | 1 |
| Pearce, RK | 1 |
| Smith, L | 1 |
| Hagan, JJ | 1 |
| Jenner, P | 2 |
| Guerrini, R | 1 |
| Calò, G | 1 |
| Bianchi, C | 1 |
| Bobes, J | 1 |
| Cañas, F | 1 |
| Rejas, J | 1 |
| Mackell, J | 1 |
| Corripio, I | 1 |
| Catafau, AM | 1 |
| Perez, V | 1 |
| Puigdemont, D | 1 |
| Mena, E | 1 |
| Aguilar, Y | 1 |
| Carrió, I | 1 |
| Alvarez, E | 1 |
| Fachineto, R | 1 |
| Alves, A | 1 |
| Callegari, L | 1 |
| Rocha, JB | 4 |
| Johnston, TH | 1 |
| Lee, J | 1 |
| Gomez-Ramirez, J | 1 |
| Fox, SH | 1 |
| Brotchie, JM | 1 |
| Ross, DE | 2 |
| Kovoor, A | 1 |
| Seyffarth, P | 1 |
| Ebert, J | 1 |
| Barghshoon, S | 1 |
| Chen, CK | 1 |
| Schwarz, S | 1 |
| Axelrod, JD | 1 |
| Cheyette, BN | 1 |
| Simon, MI | 1 |
| Lester, HA | 1 |
| Schwarz, J | 2 |
| Witschy, JK | 1 |
| Winter, AS | 1 |
| Schooler, N | 1 |
| Rabinowitz, J | 2 |
| Davidson, M | 1 |
| Harvey, PD | 1 |
| Kopala, L | 1 |
| McGorry, PD | 1 |
| Van Hove, I | 1 |
| Eerdekens, M | 1 |
| Swyzen, W | 1 |
| De Smedt, G | 1 |
| Wagner, C | 2 |
| Wondracek, DC | 1 |
| Brito, VB | 1 |
| Nogueira, CW | 1 |
| Zeni, G | 2 |
| Lenders, MW | 1 |
| Buschman, HP | 1 |
| Vergouwen, MD | 1 |
| Steur, EN | 1 |
| Kölling, P | 1 |
| Hariz, M | 1 |
| Dall'Igna, OP | 1 |
| Tort, AB | 1 |
| Souza, DO | 1 |
| Lara, DR | 1 |
| Putzhammer, A | 1 |
| Perfahl, M | 1 |
| Pfeiff, L | 1 |
| Ibach, B | 1 |
| Johann, M | 1 |
| Zitzelsberger, U | 1 |
| Hajak, G | 1 |
| Ulrich, S | 1 |
| Sandmann, U | 1 |
| Genz, A | 1 |
| Schleimer, SB | 1 |
| Johnston, GA | 1 |
| Henderson, JM | 1 |
| Lim, EC | 1 |
| Wilder-Smith, EP | 1 |
| Seet, RC | 1 |
| Grant, MJ | 1 |
| Baldessarini, RJ | 1 |
| Rosengarten, H | 1 |
| Bartoszyk, GD | 1 |
| Quartermain, D | 1 |
| Lin, Y | 1 |
| Gao, XM | 8 |
| Cooper, T | 2 |
| Suckow, RF | 1 |
| Tamminga, CA | 14 |
| Konitsiotis, S | 1 |
| Tsironis, C | 1 |
| Kiortsis, DN | 1 |
| Evangelou, A | 1 |
| Gharabawi, GM | 1 |
| Bossie, CA | 1 |
| Zhu, Y | 1 |
| Natesan, S | 1 |
| Svensson, KA | 1 |
| Reckless, GE | 1 |
| Barlow, KB | 1 |
| Johansson, AM | 1 |
| Karl, T | 1 |
| Duffy, L | 1 |
| O'brien, E | 1 |
| Matsumoto, I | 1 |
| Dedova, I | 1 |
| Wadenberg, ML | 1 |
| Wiker, C | 1 |
| Svensson, TH | 1 |
| Perottoni, J | 1 |
| Pereira, RP | 1 |
| Duggal, HS | 1 |
| Kanes, SJ | 1 |
| Tokarczyk, J | 1 |
| Siegel, SJ | 2 |
| Bilker, W | 1 |
| Abel, T | 1 |
| Kelly, MP | 1 |
| Medori, R | 1 |
| Limosin, F | 1 |
| Kumar, A | 1 |
| Hans, ML | 1 |
| Maxwell, C | 1 |
| Ehrlichman, RS | 1 |
| Metzger, K | 1 |
| Liang, Y | 1 |
| Lowman, AM | 1 |
| Zhang, Y | 1 |
| Xu, H | 1 |
| He, J | 1 |
| Yan, B | 1 |
| Jiang, W | 1 |
| Li, X | 1 |
| Li, XM | 1 |
| Currier, GW | 1 |
| Zimbroff, DL | 2 |
| Allen, MH | 1 |
| Oren, D | 1 |
| Manos, G | 1 |
| McQuade, R | 1 |
| Pikalov, AA | 1 |
| Crandall, DT | 1 |
| Thaakur, SR | 1 |
| Jyothi, B | 1 |
| Ikram, H | 1 |
| Preskorn, SH | 1 |
| Gajendiran, M | 1 |
| Praharaj, SK | 1 |
| Arora, M | 1 |
| Kantrowitz, JT | 1 |
| Srihari, VH | 1 |
| Tek, C | 1 |
| Lin, CC | 1 |
| Bai, YM | 1 |
| Chen, JY | 1 |
| Liou, YJ | 1 |
| Yamamoto, N | 1 |
| Oda, T | 1 |
| Cheng, WJ | 1 |
| Liu, HC | 1 |
| Huang, MC | 1 |
| Eudicone, JM | 1 |
| Pikalov, A | 1 |
| Kim, E | 1 |
| Kenney, C | 1 |
| Hunter, C | 1 |
| Davidson, A | 1 |
| Jankovic, J | 2 |
| Khan, A | 1 |
| Perveen, T | 1 |
| Haider, S | 1 |
| Abdul Haleem, M | 1 |
| Möller, HJ | 1 |
| Riedel, M | 1 |
| Jäger, M | 1 |
| Wickelmaier, F | 1 |
| Maier, W | 1 |
| Kühn, KU | 1 |
| Buchkremer, G | 1 |
| Heuser, I | 1 |
| Klosterkötter, J | 1 |
| Gastpar, M | 2 |
| Braus, DF | 1 |
| Schlösser, R | 1 |
| Schneider, F | 1 |
| Ohmann, C | 1 |
| Riesbeck, M | 1 |
| Gaebel, W | 1 |
| Liebman, J | 1 |
| Neale, R | 3 |
| Glassman, RB | 1 |
| Glassman, HN | 1 |
| Barbaccia, ML | 1 |
| Trabucchi, M | 1 |
| Davis, KL | 3 |
| Kastin, AJ | 1 |
| Beilstein, BA | 1 |
| Vento, AL | 2 |
| Borison, RL | 5 |
| Diamond, BI | 5 |
| Vinar, O | 1 |
| Ringwald, E | 1 |
| Lustig, A | 1 |
| Moscovici, M | 1 |
| Spiegel, R | 1 |
| Vamos, E | 1 |
| Spring, G | 1 |
| Frankel, M | 1 |
| Ungvári, G | 1 |
| Pethö, B | 1 |
| Yassa, R | 1 |
| Ananth, J | 1 |
| Porsolt, RD | 2 |
| Jalfre, M | 1 |
| Cordoba, OA | 1 |
| Faheem, AD | 1 |
| Brightwell, DR | 1 |
| Burton, GC | 1 |
| Struss, A | 1 |
| Schiele, B | 1 |
| Cross, AJ | 1 |
| Gamble, SJ | 2 |
| Bourne, RC | 1 |
| Klawans, HL | 9 |
| Goetz, CG | 5 |
| Carvey, P | 4 |
| Brown, WA | 1 |
| Gunne, LM | 7 |
| Häggström, JE | 3 |
| Pi, EH | 1 |
| Simpson, GM | 1 |
| Wagner, HN | 1 |
| Schrader, G | 1 |
| Hicks, EP | 1 |
| Fujii, Y | 1 |
| Tateyama, M | 1 |
| Kamisada, M | 1 |
| Tanoue, A | 1 |
| Takamiya, M | 1 |
| Nakajima, S | 1 |
| Itoh, H | 1 |
| Mori, A | 1 |
| Allen, RM | 1 |
| Koller, W | 1 |
| Curtin, J | 1 |
| Fields, J | 1 |
| Growdon, JH | 1 |
| Gerhardt, S | 3 |
| Liebman, JM | 3 |
| Chouinard, G | 7 |
| Young, SN | 1 |
| Annable, L | 2 |
| Reches, A | 1 |
| Hassan, MN | 1 |
| Jackson, V | 1 |
| Fahn, S | 2 |
| Sandyk, R | 8 |
| Hurwitz, MD | 1 |
| Settle, EC | 1 |
| Ayd, FJ | 3 |
| Bédard, PJ | 3 |
| Boucher, R | 3 |
| Daigle, M | 1 |
| Di Paolo, T | 1 |
| Sato, M | 2 |
| Kashihara, K | 1 |
| Harada, T | 1 |
| Sant, WW | 1 |
| Ellison, G | 5 |
| Costall, B | 2 |
| Kelly, ME | 1 |
| Naylor, RJ | 2 |
| Sundén-Kuronen, B | 1 |
| Pohto, P | 1 |
| Alanen, E | 1 |
| Davis, JM | 1 |
| Holcomb, HH | 1 |
| Sternberg, DE | 1 |
| Heninger, GR | 1 |
| Mann, SC | 1 |
| Greenstein, RA | 1 |
| Eilers, R | 1 |
| Rastogi, SK | 2 |
| Rastogi, RB | 2 |
| Singhal, RL | 2 |
| Lapierre, YD | 4 |
| Bhargava, HN | 1 |
| Carlsson, A | 1 |
| Wikström, H | 1 |
| Lerer, B | 1 |
| Van Putten, T | 2 |
| May, PR | 1 |
| Marder, SR | 3 |
| Nair, NP | 2 |
| Lal, S | 1 |
| Schwartz, G | 1 |
| Thavundayil, JX | 1 |
| Yonchev, V | 1 |
| Toreva, D | 1 |
| Margova, L | 1 |
| Yonchev, A | 1 |
| Bannet, J | 2 |
| Belmaker, RH | 2 |
| Ebstein, RP | 2 |
| Fallon, S | 1 |
| Rosenbaum, A | 1 |
| Yarbrough, GG | 1 |
| Faison, EP | 1 |
| Antolik, EK | 1 |
| Larochelle, L | 2 |
| Mizrahi, EM | 1 |
| Holtzman, D | 1 |
| Tharp, B | 1 |
| Caine, ED | 3 |
| Polinsky, RJ | 1 |
| Mueller, J | 1 |
| Aminoff, MJ | 1 |
| Shapiro, E | 1 |
| Shapiro, AK | 1 |
| Bogomolny, A | 1 |
| Erenberg, G | 1 |
| Rothner, AD | 1 |
| Wolf, ME | 1 |
| Bowie, L | 1 |
| Keener, S | 1 |
| Mosnaim, AD | 1 |
| Multani, HS | 1 |
| Varma, GK | 1 |
| Weiner, WJ | 5 |
| Werner, TR | 1 |
| Schweitzer, JW | 1 |
| Schwartz, R | 1 |
| Friedhoff, AJ | 1 |
| Gordon, JH | 2 |
| Nausieda, PA | 4 |
| Kulik, AV | 1 |
| Wilbur, R | 1 |
| Breuning, SE | 2 |
| Ferguson, DG | 2 |
| Cullari, S | 2 |
| Davidson, AB | 1 |
| Psaras, M | 1 |
| Zissis, NP | 1 |
| Mouzakis, D | 1 |
| Lyketsos, G | 1 |
| Brecher-Fride, E | 1 |
| Yanai, J | 1 |
| Smith, RC | 2 |
| Vroulis, G | 1 |
| Misra, CH | 1 |
| Schoolar, J | 1 |
| DeJohn, C | 1 |
| Korivi, P | 1 |
| Leelavathi, DE | 1 |
| Arzu, D | 1 |
| Petty, LK | 1 |
| Spar, CJ | 1 |
| Dysken, MW | 1 |
| Armenteros, JL | 2 |
| Adams, PB | 2 |
| Campbell, M | 8 |
| Eisenberg, ZW | 2 |
| Sasaki, H | 2 |
| Hashimoto, K | 2 |
| Fukui, S | 2 |
| Iyo, M | 2 |
| Owens, DG | 1 |
| Vainer, JL | 1 |
| Bélanger, MC | 1 |
| Turnier, L | 1 |
| Beaudry, P | 2 |
| Roy, JY | 1 |
| Miller, R | 1 |
| Egan, MF | 11 |
| Hurd, Y | 2 |
| Hyde, TM | 10 |
| Weinberger, DR | 3 |
| Wyatt, RJ | 4 |
| Kleinman, JE | 4 |
| Kopala, LC | 1 |
| Honer, WG | 1 |
| Delfs, JM | 1 |
| Ellison, GD | 5 |
| Mercugliano, M | 1 |
| Chesselet, MF | 2 |
| Gaither, LA | 1 |
| Kashyap, SM | 1 |
| Jaffe, E | 1 |
| Trémeau, F | 1 |
| Sharif, Z | 1 |
| Reider, R | 1 |
| Parsons, B | 1 |
| Togasaki, DM | 1 |
| Kassir, S | 1 |
| Przedborski, S | 1 |
| Kurz, M | 1 |
| Hummer, M | 1 |
| Oberbauer, H | 1 |
| Fleischhacker, WW | 3 |
| Wing, LL | 1 |
| Jones, B | 2 |
| Bloom, D | 2 |
| Addington, D | 1 |
| MacEwan, GW | 1 |
| Labelle, A | 1 |
| Beauclair, L | 2 |
| Arnott, W | 1 |
| Huang, NY | 1 |
| Kostrzewa, RM | 1 |
| Seiler, N | 1 |
| Grauffel, C | 1 |
| Elands, J | 1 |
| van den Buuse, M | 1 |
| Knödgen, B | 1 |
| Sarhan, S | 1 |
| Moran, P | 1 |
| Gobaille, S | 1 |
| Maeda, Y | 1 |
| Kitao, Y | 1 |
| Brown, RJ | 1 |
| Marchlewski, MB | 1 |
| Palao, DJ | 1 |
| Arauxo, A | 1 |
| Brunet, M | 1 |
| Bernardo, M | 1 |
| Haro, JM | 1 |
| Ferrer, J | 1 |
| Gonzalez-Monclus, E | 1 |
| Scherer, J | 1 |
| Tatsch, K | 1 |
| Oertel, WH | 1 |
| Konjarczyk, M | 1 |
| Albus, M | 1 |
| Kretschmer, BD | 1 |
| Glenthøj, B | 2 |
| Kakigi, T | 2 |
| Friedman, MB | 1 |
| Hole, K | 1 |
| Safadi, G | 1 |
| Awad, AG | 2 |
| Bransgrove, LL | 1 |
| Kelly, MW | 1 |
| Parry, TJ | 1 |
| Eberle-Wang, K | 1 |
| Lucki, I | 1 |
| Rifkin, A | 2 |
| Doddi, S | 1 |
| Karajgi, B | 1 |
| Borenstein, M | 1 |
| Munne, R | 1 |
| Thaker, GK | 3 |
| Moran, M | 1 |
| Khanna, R | 1 |
| Damodaran, SS | 1 |
| Chakraborty, SP | 1 |
| MacGibbon, GA | 1 |
| Lawlor, PA | 1 |
| Bravo, R | 1 |
| Dragunow, M | 1 |
| Lieberman, JA | 1 |
| Peacock, L | 2 |
| Gerlach, J | 8 |
| Elkashef, AM | 1 |
| Frank, JA | 1 |
| Lewis, BK | 1 |
| Shirakawa, O | 3 |
| See, RE | 9 |
| Dixon, L | 1 |
| Thaker, G | 1 |
| Conley, R | 1 |
| Ross, D | 1 |
| Cascella, N | 1 |
| Tamminga, C | 1 |
| Maeda, K | 1 |
| Sakai, K | 2 |
| Cassady, SL | 1 |
| Gattaz, WF | 2 |
| Emrich, A | 1 |
| Behrens, S | 1 |
| Kaneko, K | 1 |
| Yuasa, T | 1 |
| Miyatake, T | 1 |
| Tsuji, S | 1 |
| Ferguson, JN | 1 |
| Northoff, G | 1 |
| Wenke, J | 1 |
| Pflug, B | 1 |
| Bharucha, KJ | 1 |
| Sethi, KD | 1 |
| Jessurun, AY | 1 |
| Stek, ML | 1 |
| Meshul, CK | 3 |
| Allen, C | 1 |
| Beasley, CM | 3 |
| Tollefson, G | 1 |
| Tran, P | 1 |
| Satterlee, W | 1 |
| Sanger, T | 1 |
| Hamilton, S | 1 |
| Blin, O | 1 |
| Azorin, JM | 1 |
| Bouhours, P | 1 |
| Ferguson, J | 1 |
| Bachus, SE | 2 |
| Hamid, EH | 4 |
| Sasaki, T | 1 |
| Kennedy, JL | 1 |
| Erdmann, R | 1 |
| Hashimoto, T | 2 |
| Cooper, TB | 1 |
| Kasper, S | 2 |
| Barnas, C | 3 |
| Heiden, A | 1 |
| Volz, HP | 1 |
| Laakmann, G | 1 |
| Zeit, H | 1 |
| Pfolz, H | 1 |
| Maj, J | 1 |
| Rogóz, Z | 1 |
| Skuza, G | 1 |
| Kołodziejczyk, K | 1 |
| Mack, RJ | 1 |
| Wozniak, PJ | 1 |
| Sebree, TB | 1 |
| Wallin, BA | 1 |
| Kashkin, KB | 1 |
| Fdez Espejo, E | 1 |
| Gil, E | 1 |
| Malone, RP | 3 |
| Overall, JE | 4 |
| Riker, RR | 1 |
| Fraser, GL | 1 |
| Richen, P | 1 |
| Jann, MW | 3 |
| Crabtree, BL | 1 |
| Pitts, WM | 1 |
| Lam, YW | 1 |
| Carter, JG | 1 |
| Freeman, HL | 1 |
| Bobba, R | 1 |
| Ishida-Tokuda, K | 1 |
| Ishibashi, T | 1 |
| Nakamura, M | 1 |
| Casey, DE | 4 |
| Tollefson, GD | 2 |
| Tamura, RN | 2 |
| Tran, PV | 2 |
| Potvin, JH | 1 |
| Lane, HY | 1 |
| Chang, WH | 1 |
| Chang, YC | 1 |
| Hu, OY | 1 |
| Lin, HN | 1 |
| Hu, WH | 1 |
| Fukuoka, T | 1 |
| Nakano, M | 1 |
| Kohda, A | 1 |
| Okuno, Y | 1 |
| Matsuo, M | 1 |
| Andia, I | 1 |
| Zumarraga, M | 1 |
| Zabalo, MJ | 1 |
| Bulbena, A | 1 |
| Davila, R | 1 |
| Wright, AM | 1 |
| Bempong, J | 1 |
| Kirby, ML | 1 |
| Barlow, RL | 1 |
| Bloomquist, JR | 1 |
| de la Fuente-Fernández, R | 1 |
| Yokoyama, H | 1 |
| Kasai, N | 1 |
| Ueda, Y | 1 |
| Niwa, R | 1 |
| Konaka, R | 1 |
| Mori, N | 1 |
| Tsuchihashi, N | 1 |
| Matsue, T | 1 |
| Ohya-Nishiguchi, H | 1 |
| Kamada, H | 1 |
| Grimm, JW | 2 |
| Kruzich, PJ | 1 |
| Medoff, DR | 1 |
| Fowler, SC | 2 |
| Wang, G | 1 |
| Hernandez-Avila, CA | 1 |
| Ortega-Soto, HA | 1 |
| Jasso, A | 1 |
| Hasfura-Buenaga, CA | 1 |
| Kranzler, HR | 1 |
| Takeuchi, H | 1 |
| Ishigooka, J | 1 |
| Kobayashi, K | 1 |
| Watanabe, S | 1 |
| Miura, S | 1 |
| Baca, SM | 2 |
| Goff, DC | 2 |
| Posever, T | 1 |
| Herz, L | 1 |
| Simmons, J | 1 |
| Kletti, N | 1 |
| Lapierre, K | 1 |
| Wilner, KD | 1 |
| Law, CG | 1 |
| Ko, GN | 1 |
| Almeida, OP | 1 |
| Lee, MS | 1 |
| Kim, YK | 1 |
| Lee, SK | 1 |
| Suh, KY | 1 |
| Normann, C | 1 |
| Brandt, C | 1 |
| Berger, M | 1 |
| Walden, J | 1 |
| Zhang-Wong, J | 2 |
| Beiser, M | 2 |
| Zipursky, RB | 2 |
| Bean, G | 2 |
| Ostergaard, K | 2 |
| Sørensen, JC | 1 |
| West, MJ | 2 |
| Breier, A | 1 |
| Hamilton, SH | 1 |
| Schmitt, U | 1 |
| Dahmen, N | 2 |
| Fischer, V | 1 |
| Weigmann, H | 1 |
| Rao, ML | 1 |
| Reuss, S | 1 |
| Hiemke, C | 1 |
| Dellva, MA | 1 |
| Morgenstern, H | 1 |
| Glazer, WM | 3 |
| Ferguson, K | 1 |
| Jeste, DV | 3 |
| Lacro, JP | 1 |
| Bailey, A | 1 |
| Rockwell, E | 1 |
| Harris, MJ | 2 |
| Caligiuri, MP | 2 |
| Berk, M | 1 |
| Brook, S | 1 |
| Trandafir, AI | 1 |
| Halliday, GM | 2 |
| Pond, SM | 3 |
| Cartwright, H | 1 |
| McRitchie, DA | 1 |
| Castagnoli, N | 1 |
| Van der Schyf, CJ | 2 |
| Wirshing, DA | 1 |
| Marshall, BD | 1 |
| Green, MF | 1 |
| Mintz, J | 2 |
| Wirshing, WC | 1 |
| Weber, C | 1 |
| Rojas, VM | 1 |
| Davies, RK | 1 |
| Ikeda, H | 1 |
| Adachi, K | 1 |
| Hasegawa, M | 1 |
| Hirose, N | 1 |
| Koshikawa, N | 1 |
| Cools, AR | 1 |
| Petersen, R | 1 |
| Zimmer, J | 1 |
| Müller, R | 1 |
| Kockott, G | 1 |
| LaHoste, GJ | 1 |
| Wigal, T | 1 |
| King, BH | 1 |
| Schuck, SEB | 1 |
| Crinella, FM | 1 |
| Swanson, JM | 1 |
| Eyles, DW | 1 |
| Woods, SW | 1 |
| Colonna, L | 1 |
| Saleem, P | 1 |
| Dondey-Nouvel, L | 1 |
| Rein, W | 1 |
| Bester, A | 1 |
| Bower, CM | 1 |
| Zaka, M | 1 |
| Tipper, G | 1 |
| Wong, ML | 1 |
| Shulman, RW | 1 |
| Galili, R | 1 |
| Gil-Ad, I | 2 |
| Weizman, A | 2 |
| Melamed, E | 2 |
| Offen, D | 1 |
| Fehr, C | 1 |
| Klawe, C | 1 |
| Eicke, M | 1 |
| Szegedi, A | 1 |
| Araki, T | 1 |
| Mizutani, H | 1 |
| Matsubara, M | 1 |
| Imai, Y | 1 |
| Mizugaki, M | 1 |
| Itoyama, Y | 1 |
| Agarwal, V | 1 |
| Kumar, P | 1 |
| Bester, AM | 1 |
| Costa e Silva, JA | 1 |
| Alvarez, N | 1 |
| Mazzotti, G | 1 |
| Ospina, J | 1 |
| Larach, V | 1 |
| Starkstein, S | 1 |
| Oliva, D | 1 |
| Cousins, L | 1 |
| Tohen, M | 1 |
| Taylor, CC | 1 |
| Wang, J | 1 |
| Moore, C | 1 |
| Ossowska, K | 1 |
| Wolfarth, S | 1 |
| Wierońska, J | 1 |
| Pilc, A | 1 |
| Infante, M | 1 |
| Khandat, A | 1 |
| Berglind, WJ | 1 |
| Cruz-Velarde, JA | 1 |
| Montoto Otero, C | 1 |
| Mitchell, IJ | 1 |
| Cooper, AC | 1 |
| Griffiths, MR | 1 |
| Cooper, AJ | 1 |
| Queiroz, CM | 1 |
| Alcântara, FB | 1 |
| Yagüe, AM | 1 |
| Bibancos, T | 1 |
| Deutch, AY | 1 |
| Klintenberg, R | 1 |
| Gunne, L | 1 |
| Andrén, PE | 1 |
| Saba, P | 1 |
| Gessa, GL | 2 |
| Bhattacharya, SK | 1 |
| Sairam, K | 1 |
| Ghosal, S | 1 |
| Shtaif, B | 1 |
| Shiloh, R | 1 |
| Tauscher, J | 1 |
| Küfferle, B | 1 |
| Asenbaum, S | 1 |
| Tauscher-Wisniewski, S | 1 |
| Dill, RE | 1 |
| Dorris, RL | 1 |
| Phillips-Thonnard, I | 1 |
| Kobayashi, RM | 1 |
| Quitkin, F | 1 |
| Gochfeld, L | 1 |
| Klein, DF | 1 |
| Sayers, AC | 1 |
| Bürki, HR | 2 |
| Ruch, W | 1 |
| Asper, H | 1 |
| Carroll, BJ | 1 |
| Curtis, GC | 1 |
| Kokmen, E | 1 |
| Hale, C | 1 |
| Heins, T | 1 |
| Nohria, V | 1 |
| Owen, RT | 1 |
| Jus, A | 1 |
| Jus, K | 1 |
| Fontaine, P | 1 |
| Asnis, GM | 1 |
| Sachar, EJ | 1 |
| Langer, G | 1 |
| Halpern, FS | 1 |
| Fink, M | 1 |
| Bateman, DN | 3 |
| Dutta, DK | 2 |
| McClelland, HA | 2 |
| Rawlins, MD | 3 |
| Loudon, JB | 1 |
| Waring, H | 1 |
| Simmelsgaard, H | 1 |
| Bárány, S | 3 |
| Ingvast, A | 1 |
| Rosin, AJ | 1 |
| Margolin, DI | 1 |
| Brown, GL | 1 |
| Ebert, MH | 1 |
| Bédard, P | 1 |
| Delean, J | 1 |
| Lafleur, J | 1 |
| Tarsy, D | 1 |
| Granacher, R | 1 |
| Bralower, M | 1 |
| Weiss, B | 1 |
| Santelli, S | 1 |
| List, SJ | 1 |
| Seeman, P | 1 |
| Koller, WC | 1 |
| West, RR | 1 |
| Newgreen, DB | 1 |
| Ashford, JW | 1 |
| Ford, CV | 1 |
| Hollister, LE | 1 |
| Simonton, S | 1 |
| Hitri, A | 2 |
| Eibergen, RD | 2 |
| Carlson, KR | 2 |
| De Fraites, EG | 1 |
| Berger, PA | 1 |
| Stimmel, GL | 1 |
| Singh, MM | 1 |
| Pereira, JS | 1 |
| Bertolucci, PH | 1 |
| Ferraz, HB | 1 |
| De Andrade, LA | 1 |
| Marco, LA | 3 |
| Joshi, RS | 1 |
| Diana, M | 1 |
| Collu, M | 1 |
| Mura, A | 1 |
| Mierau, J | 1 |
| Schingnitz, G | 1 |
| Sachdev, P | 1 |
| Tang, WM | 1 |
| Lublin, H | 3 |
| Coffin, VL | 1 |
| McHuch, D | 1 |
| Chipkin, RE | 1 |
| Barnett, A | 1 |
| Ancill, R | 1 |
| Awad, G | 1 |
| Bakish, D | 2 |
| Chandrasena, R | 1 |
| Das, M | 1 |
| Durand, C | 1 |
| Elliott, D | 1 |
| Staudt, F | 1 |
| Linder, M | 1 |
| Bajulaiye, R | 1 |
| O'Connor, M | 1 |
| Rooney, MD | 1 |
| Nienaber, CP | 1 |
| Janowsky, A | 1 |
| Stallbaumer, RK | 1 |
| Taylor, B | 1 |
| Kaneda, H | 2 |
| Dale, J | 1 |
| Goodman, L | 2 |
| Saltz, BL | 1 |
| Newcomer, JW | 2 |
| Riney, SJ | 2 |
| Vinogradov, S | 2 |
| Csernansky, JG | 2 |
| Panton, D | 1 |
| Krull, AJ | 1 |
| Tran-Johnson, TK | 1 |
| Auchus, AP | 1 |
| Pickel, VM | 1 |
| Emerich, DF | 1 |
| Sanberg, PR | 1 |
| Stedman, TJ | 1 |
| Whiteford, HA | 1 |
| Eyles, D | 1 |
| Welham, JL | 1 |
| Pollock, J | 1 |
| Kornetsky, C | 1 |
| Stuppäck, CH | 2 |
| Sperner-Unterweger, B | 2 |
| Miller, C | 2 |
| Hinterhuber, H | 1 |
| Haring, C | 1 |
| Pucilowski, O | 1 |
| Eichelman, B | 1 |
| Eklund, K | 1 |
| Forsman, A | 1 |
| Cookson, JC | 1 |
| Franco, K | 1 |
| Tamburrino, M | 1 |
| Campbell, N | 1 |
| Pentz, J | 1 |
| Evans, C | 1 |
| Hagert, U | 2 |
| Meidahl, B | 2 |
| Mølbjerg, C | 1 |
| Pedersen, V | 1 |
| Rendtorff, C | 1 |
| Tolvanen, E | 1 |
| Locascio, JJ | 2 |
| Small, AM | 2 |
| Kafantaris, V | 2 |
| Ernst, M | 1 |
| Lynch, NS | 1 |
| Kastrup, O | 1 |
| Eikmeier, G | 1 |
| Bandelow, B | 1 |
| Müller, P | 2 |
| Rüther, E | 1 |
| Boyer, P | 1 |
| Lecrubier, Y | 1 |
| Puech, AJ | 1 |
| Miller, LG | 1 |
| Goldberg, RJ | 1 |
| Morris, PL | 1 |
| Lidofsky, S | 1 |
| Toga, AW | 1 |
| Deo, R | 1 |
| Soni, S | 1 |
| Rastogi, SC | 1 |
| Levine, S | 1 |
| Plant, I | 1 |
| Edwards, JG | 1 |
| Mitchell, M | 1 |
| Chanas, A | 1 |
| Laux, G | 1 |
| Klieser, E | 1 |
| Schröder, HG | 1 |
| Dittmann, V | 1 |
| Unterweger, B | 1 |
| Schubert, H | 1 |
| König, P | 1 |
| Schöny, HW | 1 |
| Bunse, J | 1 |
| Beckmann, H | 1 |
| Lindström, LH | 1 |
| Wieselgren, IM | 1 |
| Struwe, G | 1 |
| Kristjansson, E | 1 |
| Akselson, S | 1 |
| Arthur, H | 1 |
| Andersen, T | 1 |
| Lindgren, S | 1 |
| Norman, O | 1 |
| Naimell, L | 1 |
| Wålinder, J | 1 |
| Holm, AC | 1 |
| Saxena, B | 1 |
| McClure, DJ | 1 |
| Max, P | 1 |
| Manchanda, R | 1 |
| Ahlfors, UG | 1 |
| Rimön, R | 1 |
| Appelberg, B | 1 |
| Harma, P | 1 |
| Katila, H | 1 |
| Mahlanen, A | 1 |
| Mehtonen, OP | 1 |
| Naukkarinen, H | 1 |
| Outakoski, J | 1 |
| Rupniak, NM | 3 |
| Tye, SJ | 2 |
| Iversen, SD | 2 |
| Bartkó, G | 1 |
| Frecska, E | 2 |
| Horváth, S | 1 |
| Zádor, G | 1 |
| Arató, M | 1 |
| Dale, JM | 1 |
| Kaneda, N | 1 |
| Stein, MH | 1 |
| Arana, GW | 1 |
| Greenblatt, DJ | 1 |
| Dupont, R | 1 |
| Ornsteen, M | 1 |
| Harmatz, JS | 1 |
| Shader, RI | 1 |
| Sandor, P | 1 |
| Musisi, S | 1 |
| Moldofsky, H | 1 |
| Lang, A | 1 |
| Kemperman, CJ | 1 |
| van den Hoofdakker, RH | 1 |
| Gariano, RF | 1 |
| Young, SJ | 1 |
| Segal, DS | 1 |
| Groves, PM | 1 |
| Barthalmus, GT | 2 |
| Meadows, KB | 1 |
| Lazarus, A | 1 |
| Choroco, MC | 1 |
| Spencer, EK | 3 |
| Rossi, A | 1 |
| deCataldo, S | 1 |
| Bolino, F | 1 |
| Pacitti, F | 1 |
| Stratta, P | 1 |
| Casacchia, M | 1 |
| Steventon, MJ | 1 |
| Boyce, S | 1 |
| Achiron, A | 1 |
| Hemmingsen, R | 1 |
| Allerup, P | 1 |
| Bolwig, TG | 1 |
| Truong, DD | 1 |
| Hermanowicz, N | 1 |
| Rontal, M | 1 |
| Johansson, P | 1 |
| Liao, RM | 1 |
| Skjoldager, P | 1 |
| Meiselas, KD | 1 |
| Oberfield, R | 1 |
| Peselow, ED | 1 |
| Angrist, B | 2 |
| Diedrich, U | 1 |
| Prasad, C | 1 |
| Spahn, SA | 1 |
| Ikegami, H | 1 |
| Weihmuller, FB | 1 |
| Hadjiconstantinou, M | 1 |
| Bruno, JP | 1 |
| Neff, NH | 1 |
| Aravagiri, M | 1 |
| Douyon, R | 1 |
| Peselow, E | 1 |
| Rotrosen, J | 1 |
| Wagman, AM | 1 |
| Kirkpatrick, B | 2 |
| Perényi, A | 1 |
| Goswami, U | 1 |
| Majláth, E | 1 |
| Barcs, G | 1 |
| Kassay-Farkas, A | 1 |
| Fidone, GS | 1 |
| Hernandez, JM | 1 |
| Amrung, S | 1 |
| Davis, CM | 1 |
| Saran, A | 1 |
| Addy, O | 1 |
| Foliart, RH | 1 |
| Schubert, DS | 1 |
| Halaris, A | 1 |
| Campbell, W | 1 |
| Osser, DN | 1 |
| Fisher, H | 3 |
| Pendleton, R | 1 |
| Reed, TF | 2 |
| Brigham, TE | 1 |
| Aldes, LD | 2 |
| Chronister, RB | 2 |
| Vamvakides, A | 3 |
| Sexson, WR | 1 |
| Barak, Y | 1 |
| Mukherjee, S | 1 |
| Roth, SD | 1 |
| Schnur, DB | 1 |
| Tanner, CM | 1 |
| Arushanian, EB | 1 |
| McIntyre, IM | 1 |
| Gershon, S | 1 |
| Domino, EF | 1 |
| Hafez, HM | 1 |
| Benarroche, CL | 1 |
| Knudsen, P | 1 |
| Kovacic, B | 1 |
| Ruffing, D | 1 |
| Stanley, M | 1 |
| De Cuyper, H | 1 |
| Bollen, J | 1 |
| van Praag, HM | 1 |
| Verstraeten, D | 1 |
| Heim, M | 3 |
| See, R | 1 |
| Levin, E | 1 |
| Kinney, J | 1 |
| Levy, AD | 2 |
| Levin, ED | 2 |
| Morgner, J | 1 |
| Mithani, S | 1 |
| Atmadja, S | 1 |
| Baimbridge, KG | 1 |
| Fibiger, HC | 1 |
| Bruun, RD | 1 |
| Amore, M | 1 |
| Cerisoli, M | 1 |
| Campanile, S | 1 |
| Campanile, A | 1 |
| Bowers, MB | 1 |
| Swigar, ME | 1 |
| Perry, R | 3 |
| Adams, P | 1 |
| Lynch, N | 1 |
| Curren, EL | 1 |
| Nobler, MS | 1 |
| Newton, JE | 1 |
| Cannon, DJ | 1 |
| Couch, L | 1 |
| Fody, EP | 1 |
| McMillan, DE | 1 |
| Metzer, WS | 1 |
| Paige, SR | 1 |
| Reid, GM | 1 |
| Summers, BN | 1 |
| Lepore, V | 1 |
| Di Reda, N | 1 |
| Defazio, G | 1 |
| Pedone, D | 1 |
| Giovine, A | 1 |
| Lanzi, C | 1 |
| Tartaglione, B | 1 |
| Livrea, P | 1 |
| Troung, DD | 1 |
| Bressman, S | 1 |
| Shale, H | 1 |
| Sczesni, B | 1 |
| Przuntek, H | 1 |
| Povlsen, UJ | 1 |
| Noring, U | 1 |
| Korsgaard, S | 2 |
| Waehrens, J | 1 |
| Riddle, MA | 1 |
| Hardin, MT | 1 |
| Towbin, KE | 1 |
| Leckman, JF | 1 |
| Cohen, DJ | 1 |
| Galen, DM | 1 |
| Shah, C | 1 |
| White, TH | 1 |
| Kozell, L | 1 |
| Wagner, GC | 1 |
| Twery, MJ | 1 |
| Critcher, EC | 1 |
| Lewis, MH | 1 |
| Mailman, RB | 1 |
| Cooper, CW | 1 |
| Browne, JL | 1 |
| Hart, RR | 1 |
| Briggs, RS | 1 |
| Petersen, MM | 1 |
| Mann, S | 1 |
| Reavill, C | 1 |
| Marsden, CD | 1 |
| Simpson, JM | 1 |
| Peabody, CA | 1 |
| Brody, D | 1 |
| Warner, MD | 1 |
| Hama, Y | 1 |
| Ebadi, M | 1 |
| Green, WH | 1 |
| Die Trill, ML | 1 |
| Meiselas, K | 1 |
| Golden, RR | 1 |
| Deutsch, SI | 1 |
| Ornitz, EM | 1 |
| Claghorn, JL | 1 |
| Gerber, R | 1 |
| Campbell, WG | 1 |
| Raskind, MA | 1 |
| Gordon, T | 1 |
| Shaw, CM | 1 |
| Rapisarda, V | 1 |
| Bonomo, V | 1 |
| Parisi, R | 1 |
| Addonizio, G | 1 |
| Horikawa, H | 1 |
| Konagaya, M | 1 |
| Mano, Y | 1 |
| Takayanagi, T | 1 |
| Christensson, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics[NCT03430596] | Early Phase 1 | 50 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Randomized, Double-Blind, Placebo-Controlled Trial on the Efficacy of Omega-3 Supplementation With Docosahexaenoic Acid (DHA) on Tardive Dyskinesia[NCT00621634] | Phase 2 | 40 participants (Anticipated) | Interventional | 2008-02-29 | Recruiting | ||
| Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study[NCT00837707] | Phase 4 | 25 participants (Anticipated) | Interventional | 2008-06-30 | Recruiting | ||
| Independent and Synergistic Effect of Spirulina Maxima With Exercise on General Fitness, Lipid Profile and Antioxidant Capacity in Overweight and Obese Subjects[NCT02837666] | 52 participants (Actual) | Interventional | 2017-05-04 | Completed | |||
| Risperidone Versus Haloperidol Versus Placebo in the Treatment of Chronic Schizophrenia[NCT00249132] | Phase 3 | 523 participants (Actual) | Interventional | Completed | |||
| Behavior Therapy and Psychosocial Treatment for Tourette Syndrome and Chronic Tic Disorder[NCT00231985] | Phase 2 | 122 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
27 reviews available for haloperidol and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.
Topics: Adrenergic Uptake Inhibitors; Anti-Dyskinesia Agents; Antipsychotic Agents; Celiprolol; Disease Prog | 2018 |
Aripiprazole alone or in combination for acute mania.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Dr | 2013 |
Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Haloperidol; Humans; Patient Dropouts; Randomized Co | 2014 |
Pharmacogenetics in psychosis.
Topics: Antipsychotic Agents; Clozapine; Cytochrome P-450 Enzyme System; Drug Resistance; Dyskinesia, Drug-I | 2003 |
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Child; Dibenzothiazepin | 2004 |
[The use of atypical antipsychotics in the long-term care of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; | 2006 |
Tardive dyskinesia: a biological appraoch.
Topics: Animals; Antipsychotic Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haloperidol; Human | 1980 |
[Neuroleptics in 1979 (author's transl)].
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Halope | 1980 |
Lithium carbonate in the treatment of movement disorders. A critical review.
Topics: Adult; Aged; Antipsychotic Agents; Clinical Trials as Topic; Deanol; Dopamine; Double-Blind Method; | 1980 |
Prolactin levels and effects of neuroleptics.
Topics: Antipsychotic Agents; Biological Availability; Chlorpromazine; Drug Tolerance; Dyskinesia, Drug-Indu | 1983 |
Animal models of tardive dyskinesia: their use in the search for new treatment methods.
Topics: Age Factors; Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Carbidopa; Corpus Striatum; Di | 1983 |
Atypical neuroleptics: clozapine and the benzamides in the prevention and treatment of tardive dyskinesia.
Topics: Antipsychotic Agents; Benzamides; Clinical Trials as Topic; Clozapine; Dibenzazepines; Dose-Response | 1983 |
[Recent advances in clinical psychopharmacology].
Topics: Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Benzamides; Carbamazepine; Dyskine | 1984 |
Extrapyramidal side effects and tolerability of risperidone: a review.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; D | 1994 |
Prediction of outcome in first-episode schizophrenia.
Topics: Antipsychotic Agents; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Growth Hormo | 1993 |
Tardive tourettism after exposure to neuroleptic therapy.
Topics: Antipsychotic Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male | 1995 |
[Nicotine in neuropsychiatric movement disorders].
Topics: Adult; Akathisia, Drug-Induced; Brain; Child; Dyskinesia, Drug-Induced; Haloperidol; Humans; Nicotin | 1996 |
Movement disorders associated with withdrawal from high-dose intravenous haloperidol therapy in delirious ICU patients.
Topics: Adult; Critical Care; Delirium; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Infusions, In | 1997 |
Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies.
Topics: Adult; Amisulpride; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Double- | 1997 |
The relationship of pharmacology to side effects.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; D | 1997 |
Tardive dyskinesia: pathophysiology and animal models.
Topics: Age Factors; Animals; Antipsychotic Agents; Basal Ganglia; Behavior, Animal; Disease Models, Animal; | 2000 |
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Administration Schedule; | 2000 |
The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy?
Topics: Animals; Antipsychotic Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Haloperidol; Humans; | 2002 |
[30 years experience with haloperidol].
Topics: Brain; Dopamine Antagonists; Dyskinesia, Drug-Induced; Haloperidol; Humans; Psychotic Disorders | 1991 |
A systematic approach to pharmacotherapy in patients with neuroleptic-resistant psychoses.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Human | 1989 |
[Neuroleptic parkinsonism and tardive dyskinesia and methods of pharmacologically correcting these pathologic conditions (review)].
Topics: Animals; Antipsychotic Agents; Cats; Cholinergic Fibers; Corpus Striatum; Dopamine; Dyskinesia, Drug | 1985 |
[Effect of glycine-steatamide or glutamic acid palmitamide on oral dyskinesia, obtained by a single administration of haloperidol combined with GABA-linoleamide in rats].
Topics: Animals; Drug Combinations; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Glutamates; G | 1988 |
81 trials available for haloperidol and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Potential diagnostic markers of olanzapine efficiency for acute psychosis: a focus on peripheral biogenic amines.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers; Dopamine; Dyskinesia, Drug-Ind | 2017 |
Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Black People; Double-Blind Method; Dyskinesia, Drug-I | 2009 |
Efficacy of sodium valproate and haloperidol in the management of acute mania: a randomized open-label comparative study.
Topics: Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Dyskinesia, Drug-Induced; Female; Haloperidol | 2010 |
A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Resistance; Drug-Related Side Effects and Adv | 2011 |
Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; | 2011 |
Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania.
Topics: Acute Disease; Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Body Wei | 2012 |
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Depression; Dopamine Antagonists; Dyskinesia, Dru | 2003 |
Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Dose-Response Rel | 2003 |
A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Drug Interactions; Dyskinesia, Drug-In | 2004 |
A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Dibenzothiazepines; Drug Administration Schedule; Dyskinesia, Drug-Indu | 2004 |
Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Dyskinesia, Drug-Induced; Follow-Up St | 2004 |
Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzamides; Drug Resistance; Dyskinesia, Drug-Induced; Female; Haloperi | 2005 |
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Ind | 2005 |
Performance of diadochokinetic movements in schizophrenic patients.
Topics: Analysis of Variance; Antipsychotic Agents; Biomechanical Phenomena; Case-Control Studies; Dose-Resp | 2005 |
Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dysk | 2007 |
Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Do | 2007 |
Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dysk | 2008 |
Lithium carbonate in the treatment of movement disorders. A critical review.
Topics: Adult; Aged; Antipsychotic Agents; Clinical Trials as Topic; Deanol; Dopamine; Double-Blind Method; | 1980 |
Atypical neuroleptics: clozapine and the benzamides in the prevention and treatment of tardive dyskinesia.
Topics: Antipsychotic Agents; Benzamides; Clinical Trials as Topic; Clozapine; Dibenzazepines; Dose-Response | 1983 |
Antimanic effect of clonazepam.
Topics: Acute Disease; Adult; Affective Disorders, Psychotic; Benzodiazepinones; Bipolar Disorder; Clonazepa | 1983 |
Haloperidol: a quarter century of experience.
Topics: Aged; Basal Ganglia Diseases; Bipolar Disorder; Clinical Trials as Topic; Dosage Forms; Drug Adminis | 1983 |
Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Resistance; Dyskinesia, Drug-Induced; Female; Haloperid | 1994 |
Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Fe | 1995 |
Extrapyramidal side effects of clozapine and haloperidol.
Topics: Adult; Akathisia, Drug-Induced; Basal Ganglia Diseases; Clozapine; Dyskinesia, Drug-Induced; Female; | 1995 |
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind M | 1993 |
Haloperidol: therapeutic window in schizophrenia.
Topics: Adult; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male | 1994 |
A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Arousal; Clopenthixol; | 1994 |
Dosage of haloperidol for mania.
Topics: Adult; Bipolar Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Ind | 1994 |
Clozapine in tardive dyskinesia: observations from human and animal model studies.
Topics: Adult; Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dyskinesia, Drug-Induced; F | 1994 |
Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; | 1993 |
Pharmacologic relationship of antisaccade and dyskinesia in schizophrenic patients.
Topics: Adult; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Middle Aged; Saccades; Schizophr | 1993 |
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Dose-Respon | 1996 |
Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Double-Blind Method; Drug The | 1996 |
Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzothiazoles; Dopamine Agonists; Drug Therap | 1997 |
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Chro | 1997 |
Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskine | 1997 |
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration | 1997 |
Differential effect of haloperidol and clozapine on plasma homovanillic acid in elderly schizophrenic patients with or without tardive dyskinesia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Clozapine; Dyskinesia, Drug-Induced; Female; Haloperi | 1998 |
Treatment of inhalant-induced psychotic disorder with carbamazepine versus haloperidol.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Dyskinesia, Drug-Induced; Haloperidol; | 1998 |
An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug | 1998 |
A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia.
Topics: Adult; Affect; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Dr | 1998 |
Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Behavioral Symptoms; Ben | 1999 |
Optimal haloperidol dosage in first-episode psychosis.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administra | 1999 |
Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
Topics: Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-Induced; Haloperidol; H | 1999 |
A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cannabis; Double-Blind Method; Dyskinesia, Drug-Induce | 1999 |
Risperidone in treatment-refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Brief Psychiatric Rating Scale; Cholinergic Ant | 1999 |
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Administration Schedule; | 2000 |
Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Chronic Disease; Dyskinesia, Drug-Induce | 2000 |
Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperi | 2001 |
The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cognition; Double-Blind Method; Dyskinesia, | 2001 |
Metoclopramide and haloperidol in tardive dyskinesia.
Topics: Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug- | 1979 |
Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine.
Topics: Aged; Biperiden; Clinical Trials as Topic; Clozapine; Dibenzazepines; Drug Therapy, Combination; Dys | 1978 |
A dose-finding study with remoxipride in the acute treatment of schizophrenic patients.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Haloperidol; Humans | 1992 |
Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.
Topics: Adult; Aged; Biomarkers; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Ind | 1992 |
High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics.
Topics: Age Factors; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Haloperidol; Humans; Incidence; Ma | 1992 |
Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Haloperido | 1991 |
[Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind study].
Topics: Adult; Antipsychotic Agents; Dibenzothiepins; Double-Blind Method; Dyskinesia, Drug-Induced; Female; | 1991 |
[Zotepine: treatment of schizophrenic patients with predominantly negative symptoms. A double-blind study vs. haloperidol].
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dibenzothiepins; Double-Blind Method; Dyskinesia, Drug | 1991 |
Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Dys | 1991 |
Side effects during long-term treatment with depot antipsychotic medication.
Topics: Akathisia, Drug-Induced; Delayed-Action Preparations; Double-Blind Method; Dyskinesia, Drug-Induced; | 1991 |
Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia.
Topics: Adult; Aged; Clopenthixol; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Human | 1991 |
Treatment of positive and negative symptoms: pharmacologic approaches.
Topics: Adult; Amisulpride; Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug | 1990 |
Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzamides; Dose-Response Relationship | 1990 |
A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzamides; Dose-Response Relationship | 1990 |
A double-blind comparative multicentre study of remoxipride and haloperidol in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzamides; Dose-Response Relationship, Drug | 1990 |
Experiences of long-term treatment with remoxipride: efficacy and tolerability.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzamides; Chronic Disease; Double-Blind Method; Dys | 1990 |
A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzamides; Canada; Dose-Response Relationsh | 1990 |
Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzamides; Dose-Response Relationship, Drug; Double- | 1990 |
The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial.
Topics: Adult; Benztropine; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Halope | 1991 |
Tourette syndrome: a follow-up study.
Topics: Adolescent; Adult; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Haloperidol; Humans; Long-Te | 1990 |
A pilot study of the role of prophylactic antiparkinson treatment during neuroleptic therapy.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Haloperidol; Hu | 1989 |
A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Clinical Trials as Topic; Delayed-Ac | 1989 |
Molindone and haloperidol in tardive dyskinesia.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Dose-Response Relationship, Drug; Dy | 1985 |
Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Biperiden; Chlorprothixene; Dyskinesia, Drug-I | 1986 |
Clonazepam, haloperidol, and clonidine in tic disorders.
Topics: Child; Clinical Trials as Topic; Clonazepam; Clonidine; Drug Therapy, Combination; Dyskinesia, Drug- | 1988 |
[The effects of neuroleptics on tardive dyskinesias. A video-controlled, randomized study of chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden].
Topics: Aged; Biperiden; Chlorprothixene; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Female; Halope | 1987 |
The therapeutic index of haloperidol in newly admitted schizophrenic patients.
Topics: Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Patient Compl | 1987 |
Atypical and typical neuroleptics and tardive dyskinesia.
Topics: Double-Blind Method; Dyskinesia, Drug-Induced; Haloperidol; Humans; Indoles; Male; Middle Aged; Moli | 1987 |
Neuroleptic-related dyskinesias in autistic children: a prospective study.
Topics: Autistic Disorder; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Dyskinesi | 1985 |
Should autistic children be treated with haloperidol?
Topics: Autistic Disorder; Child; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Haloperidol; Hospitali | 1985 |
Review of clinical and laboratory experiences with molindone hydrochloride.
Topics: Akathisia, Drug-Induced; Basal Ganglia Diseases; Clinical Trials as Topic; Dose-Response Relationshi | 1985 |
454 other studies available for haloperidol and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Indoline and piperazine containing derivatives as a novel class of mixed D(2)/D(4) receptor antagonists. Part 2: asymmetric synthesis and biological evaluation.
Topics: Amphetamine; Animals; Antipsychotic Agents; Binding, Competitive; Catalepsy; Central Nervous System | 2002 |
Antipsychotic Behavioral Phenotypes in the Mouse Collaborative Cross Recombinant Inbred Inter-Crosses (RIX).
Topics: Animals; Antipsychotic Agents; Dyskinesia, Drug-Induced; Haloperidol; Humans; Mastication; Mice; Phe | 2020 |
Protective effect of hesperetin against haloperidol-induced orofacial dyskinesia and catalepsy in rats.
Topics: Animals; Behavior, Animal; Brain; Catalepsy; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Glutat | 2018 |
Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Clozapine; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dys | 2017 |
Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors.
Topics: Animals; Antioxidants; Antipsychotic Agents; Behavior, Animal; Brain; Cannabidiol; Corpus Striatum; | 2018 |
Oral administration of haloperidol at clinically recommended doses elicits smaller parkinsonian effects but more tardive dyskinesia in rats.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Behavior, Animal; Dyskinesia, Drug-Induced; Exp | 2013 |
A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic Agents; Analysis of Variance; Animals; Anti-Dyskinesia | 2013 |
Extract of Ginkgo biloba is equivalent to vitamin E in attenuating and preventing vacuous chewing movements in a rat model of tardive dyskinesia.
Topics: Animals; Antioxidants; Antipsychotic Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Free | 2013 |
Tardive dyskinesia induced by a switch from haloperidol depot to paliperidone palmitate.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Isoxazoles; Pali | 2013 |
Contribution of the mGluR7 receptor to antiparkinsonian-like effects in rats: a behavioral study with the selective agonist AMN082.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzhydryl Compounds; Brain; Catalepsy; Disease Mod | 2013 |
Anandamide attenuates haloperidol-induced vacuous chewing movements in rats.
Topics: Animals; Antipsychotic Agents; Arachidonic Acids; Cannabinoid Receptor Agonists; Cannabinoid Recepto | 2014 |
An adaptive role of TNFα in the regulation of striatal synapses.
Topics: Animals; Biotinylation; CA1 Region, Hippocampal; Catalepsy; Corpus Striatum; Dopamine Antagonists; D | 2014 |
Haloperidol-induced extra pyramidal symptoms attenuated by imipramine in rats.
Topics: Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Brain; Disease Models, Animal; Dyskines | 2014 |
Effects of dopamine uptake inhibitor MRZ-9547 in animal models of Parkinson's disease.
Topics: Acetamides; Animals; Brain; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Thera | 2015 |
Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.
Topics: Aminobutyrates; Animals; Antiparkinson Agents; Catalepsy; Dyskinesia, Drug-Induced; Excitatory Amino | 2015 |
NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Catalepsy; Disease Models, Animal; Drug Int | 2015 |
Medication-induced acute dystonic reaction: the challenge of diagnosing movement disorders in the intensive care unit.
Topics: Antipsychotic Agents; Benzodiazepines; Brain; Diphenhydramine; Dyskinesia, Drug-Induced; Haloperidol | 2015 |
Failure to suppress low-frequency neuronal oscillatory activity underlies the reduced effectiveness of random patterns of deep brain stimulation.
Topics: Action Potentials; Animals; Central Nervous System Stimulants; Deep Brain Stimulation; Dopamine D2 R | 2016 |
Nigella sativa Oil Reduces Extrapyramidal Symptoms (EPS)-Like Behavior in Haloperidol-Treated Rats.
Topics: Animals; Antipsychotic Agents; Astrocytes; Basal Ganglia Diseases; Caudate Nucleus; Dyskinesia, Drug | 2016 |
Ginkgo biloba leaf extract and alpha-tocopherol attenuate haloperidol-induced orofacial dyskinesia in rats: Possible implication of antiapoptotic mechanisms by preventing Bcl-2 decrease and Bax elevation.
Topics: alpha-Tocopherol; Animals; Antioxidants; Antipsychotic Agents; bcl-2-Associated X Protein; Brain; Di | 2016 |
The Relationship Between Early Haloperidol Response and Associated Extrapyramidal Side Effects.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Brief Psychiatric Rating Scale; Dyskinesia, Dr | 2017 |
Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Dopamine; Dyskinesia, Drug-Induced; Haloperidol; Ma | 2008 |
Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Topics: Adult; Alleles; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Genetic Markers; Genotype; H | 2008 |
Activation of striatal inflammatory mediators and caspase-3 is central to haloperidol-induced orofacial dyskinesia.
Topics: Animals; Antipsychotic Agents; Caspase 3; Corpus Striatum; Dose-Response Relationship, Drug; Dyskine | 2008 |
The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antipsychotic Agents; Caffeine; Catalepsy; Cebus; Corpus | 2008 |
Behavioral effects of 1-(m-chlorophenyl)piperazine (m-CPP) in a rat model of tardive dyskinesia.
Topics: Animals; Anxiety; Behavior, Animal; Disease Models, Animal; Dopamine Antagonists; Dyskinesia, Drug-I | 2008 |
Co-administration of nitric oxide (NO) donors prevents haloperidol-induced orofacial dyskinesia, oxidative damage and change in striatal dopamine levels.
Topics: Animals; Antipsychotic Agents; Arginine; Chromatography, High Pressure Liquid; Citrulline; Dopamine; | 2009 |
Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Belgium; Benzodiazepines; Brief Psychiatric Rat | 2009 |
In vivo microdialysis studies of striatal level of neurotransmitters after haloperidol and chlorpromazine administration.
Topics: Animals; Antipsychotic Agents; Basal Ganglia; Behavior, Animal; Catalepsy; Chlorpromazine; Corpus St | 2009 |
Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats.
Topics: Animals; Antioxidants; Antipsychotic Agents; Brain; Catalepsy; Dose-Response Relationship, Drug; Dys | 2009 |
Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Sch | 2009 |
Righting elicited by novel or familiar auditory or vestibular stimulation in the haloperidol-treated rat: rat posturography as a model to study anticipatory motor control.
Topics: Acoustic Stimulation; Animals; Catalepsy; Cues; Dopamine Antagonists; Dyskinesia, Drug-Induced; Halo | 2009 |
Effects of omega-3 essential fatty acids (omega-3 EFAs) on motor disorders and memory dysfunction typical neuroleptic-induced: behavioral and biochemical parameter.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Disease Models, An | 2010 |
Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopam | 2009 |
Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice.
Topics: Animals; Antipsychotic Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, D | 2010 |
Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Cholinesterase Inhibitors; Dyskinesia, Drug-Induced; Female; Genetic | 2010 |
Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats.
Topics: Animals; Benzothiazoles; Catalepsy; Delayed-Action Preparations; Disease Models, Animal; Dopamine; D | 2010 |
Novel 8-(furan-2-yl)-3-substituted thiazolo [5,4-e][1,2,4] triazolo[1,5-c] pyrimidine-2(3H)-thione derivatives as potential adenosine A(2A) receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antipsychotic Agents; Catalepsy; Cell Line; Cell Membran | 2010 |
Treatment of a tardive dyskinesia patient with temporomandibular disorder: a case report.
Topics: Aged; Antipsychotic Agents; Botulinum Toxins, Type A; Bruxism; Clozapine; Dyskinesia, Drug-Induced; | 2010 |
Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dose-Re | 2010 |
Protective effect of Morus alba leaves on haloperidol-induced orofacial dyskinesia and oxidative stress.
Topics: Animals; Dyskinesia, Drug-Induced; Haloperidol; Lipid Peroxidation; Male; Morus; Movement Disorders; | 2010 |
Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors.
Topics: Animals; Catalepsy; Cocaine; Corpus Striatum; Dopamine Agents; Dopamine and cAMP-Regulated Phosphopr | 2010 |
Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dyskinesia, Drug-Induced; Globus P | 2010 |
Haloperidol-loaded polysorbate-coated polymeric nanocapsules increase its efficacy in the antipsychotic treatment in rats.
Topics: Amphetamine; Animals; Antipsychotic Agents; Chemical Phenomena; Disease Models, Animal; Dyskinesia, | 2011 |
Reversal of haloperidol-induced motor deficits by mianserin and mesulergine in rats.
Topics: Animals; Antipsychotic Agents; Catalepsy; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Ha | 2011 |
Curcumin prevents haloperidol-induced development of abnormal oro-facial movements: possible implications of Bcl-XL in its mechanism of action.
Topics: Animals; Antipsychotic Agents; bcl-X Protein; Curcumin; Dyskinesia, Drug-Induced; Enzyme Inhibitors; | 2011 |
Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats.
Topics: Aminopyridines; Animals; Antipsychotic Agents; Brain Chemistry; Catalepsy; Dyskinesia, Drug-Induced; | 2011 |
Posterior hypothalamic nucleus deep brain stimulation restores locomotion in rats with haloperidol-induced akinesia but not skilled forelimb use in pellet reaching and lever pressing.
Topics: Adrenergic Agents; Animals; Anti-Dyskinesia Agents; Conditioning, Operant; Deep Brain Stimulation; D | 2011 |
Alpha-phenyl-N-tert-butylnitrone prevents oxidative stress in a haloperidol-induced animal model of tardive dyskinesia: investigating the behavioural and biochemical changes.
Topics: Animals; Catalase; Corpus Striatum; Cyclic N-Oxides; Dyskinesia, Drug-Induced; Glutathione; Haloperi | 2011 |
B vitamins attenuate haloperidol-induced orofacial dyskinesia in rats: possible involvement of antioxidant mechanisms.
Topics: Animals; Antioxidants; Antipsychotic Agents; Behavior, Animal; Drug Therapy, Combination; Dyskinesia | 2011 |
The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade.
Topics: Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Choice Behavior; Depression; Dopamine | 2012 |
Reversal of haloperidol-induced orofacial dyskinesia by Murraya koenigii leaves in experimental animals.
Topics: Alkaloids; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Re | 2012 |
Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Dopamine Plasma Membrane Transport Protei | 2012 |
An animal model to study the molecular basis of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Apoptosis; Behavior, Animal; Caspase 3; Clozapine; Disease Models, An | 2012 |
Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
Topics: Allosteric Regulation; Aminobutyrates; Anilides; Animals; Catalepsy; Cyclohexanecarboxylic Acids; Di | 2013 |
The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
Topics: Aminobutyrates; Animals; Benzoates; Catalepsy; Disease Models, Animal; Dopamine; Dopamine D2 Recepto | 2013 |
Haloperidol-loaded polysorbate-coated polymeric nanocapsules decrease its adverse motor side effects and oxidative stress markers in rats.
Topics: Animals; Drug Carriers; Dyskinesia, Drug-Induced; Haloperidol; Male; Motor Activity; Nanocapsules; O | 2012 |
Ameliorative effect of yokukansan on vacuous chewing movement in haloperidol-induced rat tardive dyskinesia model and involvement of glutamatergic system.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Drugs, Chinese Herbal; Dyskinesi | 2012 |
Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment.
Topics: Animals; Antipsychotic Agents; Corpus Striatum; Dopamine Antagonists; Dyskinesia, Drug-Induced; Halo | 2002 |
Discrimination of morphine- and haloperidol-induced muscular rigidity and akinesia/catalepsy in simple tests in rats.
Topics: Analgesics, Opioid; Animals; Antipsychotic Agents; Catalepsy; Dyskinesia, Drug-Induced; Haloperidol; | 2002 |
[Improvement of tardive dyskinesia after treatment with olanzapine].
Topics: Affective Disorders, Psychotic; Aged; Benzodiazepines; Depressive Disorder, Major; Drug Therapy, Com | 2002 |
Lesioning the thalamus for dyskinesia.
Topics: Antiparkinson Agents; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dyskinesias; Electrocoagulatio | 2001 |
The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats.
Topics: Animals; Antipsychotic Agents; Cerebellum; Corpus Striatum; Dose-Response Relationship, Drug; Dyskin | 2003 |
Possible mechanism of action in melatonin attenuation of haloperidol-induced orofacial dyskinesia.
Topics: Animals; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Free Radicals; Haloperidol; Lip | 2003 |
Ballism associated with bupropion use.
Topics: Adult; Bupropion; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Oxazepam | 2003 |
Effect of Emblica officinalis tannoids on a rat model of tardive dyskinesia.
Topics: Animals; Anti-Dyskinesia Agents; Anticonvulsants; Antioxidants; Brain; Disease Models, Animal; Dyski | 2000 |
Clozapine and tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Fema | 2003 |
Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapine and tiapride.
Topics: Aged; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Dysk | 2003 |
Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesia.
Topics: Administration, Oral; Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, | 2003 |
Reversal of haloperidol-induced orofacial dyskinesia by quercetin, a bioflavonoid.
Topics: Animals; Antipsychotic Agents; Brain; Catalase; Dose-Response Relationship, Drug; Dyskinesia, Drug-I | 2003 |
Antidyskinetic effects of risperidone on animal models of tardive dyskinesia in mice.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relations | 2003 |
Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia.
Topics: Animals; Antipsychotic Agents; Catalase; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; | 2003 |
Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Corpus Striatum; Cyclic GMP; Dyskinesia, Drug-Induce | 2003 |
Relationship of orofacial movements to behavioural repertoire as assessed topographically over the course of 6-month haloperidol treatment followed by 4-month withdrawal.
Topics: Animals; Behavior, Animal; Dopamine Antagonists; Dyskinesia, Drug-Induced; Exploratory Behavior; Hal | 2003 |
Role of aging and striatal nitric oxide synthase activity in an animal model of tardive dyskinesia.
Topics: Aging; Analysis of Variance; Animals; Behavior, Animal; Comorbidity; Corpus Striatum; Disease Models | 2003 |
Effect of Withania somnifera root extract on haloperidol-induced orofacial dyskinesia: possible mechanisms of action.
Topics: Animals; Antipsychotic Agents; Catalase; Disease Models, Animal; Dose-Response Relationship, Drug; D | 2003 |
Ultrastructural correlates of haloperidol-induced oral dyskinesias in rats: a study of unlabeled and enkephalin-labeled striatal terminals.
Topics: Animals; Antipsychotic Agents; Corpus Striatum; Dendrites; Dyskinesia, Drug-Induced; Enkephalins; Ha | 2003 |
Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia.
Topics: Animals; Antioxidants; Antipsychotic Agents; Behavior, Animal; Brain; Catalase; Disease Models, Anim | 2003 |
Differential effects of antipsychotics on haloperidol-induced vacuous chewing movements and subcortical gene expression in the rat.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Dyskinesia, Drug-Induced; Gene Exp | 2003 |
Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report.
Topics: Amphetamine-Related Disorders; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; | 2003 |
Maternal haloperidol therapy associated with dyskinesia in a newborn.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Clonazepam; Dyskinesia, Drug-Induced; Female; Haloperi | 2003 |
Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats.
Topics: Aging; Analysis of Variance; Animals; Behavior, Animal; Cell Count; Disease Models, Animal; Drug Adm | 2003 |
Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Sched | 2003 |
Memantine attenuates the increase in striatal preproenkephalin mRNA expression and development of haloperidol-induced persistent oral dyskinesias in rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Cell Count; Corpus Striatum; Dopamine Antagonists; | 2003 |
Short-term, D2 receptor blockade induces synaptic degeneration, reduces levels of tyrosine hydroxylase and brain-derived neurotrophic factor, and enhances D2-mediated firing in the ventral pallidum.
Topics: Animals; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Cell Survival; Disease Models, Ani | 2004 |
Ritanserin counteracts both rat vacuous chewing movements and nigro-striatal tyrosine hydroxylase-immunostaining alterations induced by haloperidol.
Topics: Animals; Antipsychotic Agents; Cell Size; Dyskinesia, Drug-Induced; Haloperidol; Immunohistochemistr | 2004 |
Haloperidol versus risperidone on rat "early onset" vacuous chewing.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dose-Respons | 2004 |
Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia.
Topics: Animals; Cycloserine; Disease Models, Animal; Dyskinesia, Drug-Induced; Glycine; Haloperidol; Mastic | 2004 |
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Diagnostic and Statistical Manual | 2004 |
Effects of haloperidol on cholinergic striatal interneurons: relationship to oral dyskinesias.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cell Count; Choline O-Acetyltransferase; Dyskinesia | 2004 |
Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia.
Topics: Antipsychotic Agents; Catechol O-Methyltransferase; Codon; DNA Primers; Dopamine; Dyskinesia, Drug-I | 2004 |
Unusual compulsive motor activity during treatment with clothiapine in a mentally retarded adolescent.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Compulsive Be | 2004 |
Docosahexaenoic acid reduces haloperidol-induced dyskinesias in mice: involvement of Nur77 and retinoid receptors.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzoates; Biphenyl Compounds; Disease Models, | 2004 |
Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Binding Sites; C | 2004 |
Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dose-Response Relationship, Drug; | 2004 |
Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release.
Topics: Animals; Dopamine Antagonists; Dyskinesia, Drug-Induced; Glutamic Acid; Haloperidol; Male; Microdial | 2004 |
Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.
Topics: Animals; Antipsychotic Agents; Brain; Disease Models, Animal; Drug Administration Schedule; Dyskines | 2005 |
A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Amantadine; Animals; Anti-Dyskinesia Age | 2005 |
Tardive dyskinesia and second-generation antipsychotics.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Haloperidol; Humans; Research Design; Risk Fa | 2005 |
Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Benzodiazepines; Disease Models, Animal; Dopamine A | 2005 |
D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Antipsych | 2005 |
Improvement in tardive dyskinesia with aripiprazole use.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Interactions; Drug Therapy, Combination; | 2005 |
High fat diet increases the incidence of orofacial dyskinesia and oxidative stress in specific brain regions of rats.
Topics: Analysis of Variance; Animals; Brain; Cerebellum; Cerebral Cortex; Dietary Fats; Dyskinesia, Drug-In | 2005 |
Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain.
Topics: Animals; Antioxidants; Azoles; Behavior, Animal; Brain; Cerebral Cortex; Corpus Striatum; Dyskinesia | 2005 |
Long term results of unilateral posteroventral pallidotomy for antipsychotic drug induced tardive dyskinesia.
Topics: Athetosis; Chorea; Clopenthixol; Delayed-Action Preparations; Dominance, Cerebral; Drug Therapy, Com | 2005 |
Cinnarizine has an atypical antipsychotic profile in animal models of psychosis.
Topics: Amphetamine; Animals; Antipsychotic Agents; Calcium Channel Blockers; Catalepsy; Central Nervous Sys | 2005 |
Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Chromatography, High Pressure Liquid; Cross | 2005 |
Novel oral drug administration in an animal model of neuroleptic therapy.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Brain; Clozapine | 2005 |
A blessing in disguise: resolution of tardive dyskinesia with development of cervical myelitis.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Cervical Vertebrae; Dyskinesia, Drug-Induced; Follow- | 2006 |
Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Delusions; Depressive Disorder, Major; Dyskinesia, Drug-Induced; | 2005 |
The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Behavior, | 2006 |
Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperid | 2006 |
Effects of N-methyl-D-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesias.
Topics: Allosteric Regulation; Amantadine; Animals; Antipsychotic Agents; Dextrorphan; Dose-Response Relatio | 2006 |
New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Haloperidol; Humans; Inciden | 2006 |
The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor sid
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Binding, Competitive; Dihydroxyphenylalanine; Dop | 2006 |
Behavioural effects of chronic haloperidol and risperidone treatment in rats.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Disease Models, Animal; Dopamine Antagonists; | 2006 |
Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents | 2007 |
Effects of diphenyl-diselenide on orofacial dyskinesia model in rats.
Topics: Animals; Benzene Derivatives; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, | 2006 |
Atypical antipsychotics, tardive dyskinesia, and D(2) receptors.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; Haloperidol; Humans; Mal | 2006 |
Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Acoustic Stimulation; Animals; Antipsychotic Agents; Behavior, | 2007 |
Reversal of haloperidol-induced extrapyramidal symptoms by buspirone: a time-related study.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Ataxia; Buspirone; Catalepsy; Dyskinesia, Drug-I | 2007 |
Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Body Weight; Chlorpromazine; Clozapine; Dopamine; Dyskinesia, Drug-In | 2007 |
Protective effect of adenosine reuptake inhibitors in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
Topics: Animals; Behavior, Animal; Brain; Catalase; Dipyridamole; Dopamine; Dose-Response Relationship, Drug | 2007 |
Evaluation of in vitro release and in vivo efficacy of mPEG-PLA-haloperidol conjugate micelle-like structures.
Topics: Animals; Anti-Dyskinesia Agents; Delayed-Action Preparations; Drug Delivery Systems; Dyskinesia, Dru | 2007 |
Quetiapine reverses altered locomotor activity and tyrosine hydroxylase immunoreactivity in rat caudate putamen following long-term haloperidol treatment.
Topics: Animals; Antipsychotic Agents; Caudate Nucleus; Dibenzothiazepines; Dyskinesia, Drug-Induced; Halope | 2007 |
Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Buspirone; Chromatography, Hi | 2007 |
Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study.
Topics: Animals; Anti-Dyskinesia Agents; Antioxidants; Antipsychotic Agents; Catalase; Chlorpromazine; Diaze | 2007 |
Neurochemical changes associated with chronic administration of typical antipsychotics and its relationship with tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Brain; Chlorpromazine; Dopamine; Dyskinesia, Drug-I | 2007 |
Effect of spirulina maxima on the haloperidol induced tardive dyskinesia and oxidative stress in rats.
Topics: Animals; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Lipid Peroxidation | 2007 |
Neurochemical and behavioral effects of m-CPP in a rat model of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striat | 2007 |
The evolution of antipsychotic drug therapy: reserpine, chlorpromazine, and haloperidol.
Topics: Antipsychotic Agents; Chlorpromazine; Dyskinesia, Drug-Induced; Europe; Haloperidol; History, 20th C | 2007 |
Differential effects of spinal 5-HT1A receptor activation and 5-HT2A/2C receptor desensitization by chronic haloperidol.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amphetamines; Animals; Antipsychotic Agents; Dyskinesia, Dru | 2007 |
Pisa syndrome: acute and tardive forms.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dystonia; Haloperidol; Humans; Male; Schizoph | 2007 |
Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Dose-Response Relationship, Drug; D | 2007 |
Treatment of clozapine-associated tardive dyskinesia.
Topics: Adult; Anti-Dyskinesia Agents; Antipsychotic Agents; Clozapine; Cross-Over Studies; Dibenzothiepins; | 2008 |
Modulatory effect of neurosteroids in haloperidol-induced vacuous chewing movements and related behaviors.
Topics: Animals; Behavior, Animal; Catalase; Corpus Striatum; Dehydroepiandrosterone Sulfate; Dopamine; Dose | 2008 |
Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
Topics: Animals; Antipsychotic Agents; Brain Diseases; Control Groups; Disease Models, Animal; Dopamine; Dys | 2008 |
Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
Topics: Animals; Anti-Anxiety Agents; Anti-Dyskinesia Agents; Antipsychotic Agents; Behavior, Animal; Body W | 2008 |
Methamphetamine psychosis in which tardive dystonia was successfully treated with clonazepam.
Topics: Aged; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Biperiden; Central Nervous Syst | 2007 |
Olanzapine monotherapy for late-onset vocal tics in a schizophrenic patient.
Topics: Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Magnet | 2007 |
Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Dyskinesia, Drug-I | 2007 |
U-74500A (lazaroid), a 21-aminosteroid attenuates neuroleptic-induced orofacial dyskinesia.
Topics: Animals; Antioxidants; Antipsychotic Agents; Chlorpromazine; Disease Models, Animal; Dyskinesia, Dru | 2007 |
Metoclopramide, an increasingly recognized cause of tardive dyskinesia.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Amitriptyline; Dyskinesia, Drug-Induced; Haloperidol; | 2008 |
Increase in the effectiveness of somatodendritic 5-HT-1A receptors in a rat model of tardive dyskinesia.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Corpus Striatum; Disease Models, Animal; Dopamine A | 2007 |
Neuroleptic-induced acute dyskinesias in squirrel monkeys: correlation with propensity to cause extrapyramidal side effects.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Baclofen; Basal Ganglia Diseases; Clozapine; Diaz | 1980 |
Oral dyskinesia in brain-damaged rats withdrawn from a neuroleptic: implication for models of tardive dyskinesia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Brain; Chlorpromazine; Di | 1980 |
MSH and MIF-I in animal models of tardive dyskinesia.
Topics: Animals; Apomorphine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Human | 1980 |
Anticholinergics promote neuroleptic-induced tardive dyskinesia.
Topics: Amantadine; Animals; Antipsychotic Agents; Benztropine; Dextroamphetamine; Drug Synergism; Dyskinesi | 1980 |
[Effect of high single doses of bromocriptine in schizophrenic patients with elevated serum prolactin levels and extrapyramidal side effects associated with neuroleptic treatment (author's transl)].
Topics: Adult; Antipsychotic Agents; Bromocriptine; Chlorpromazine; Chronic Disease; Dose-Response Relations | 1980 |
New data on lithium and haloperidol incompatibility.
Topics: Antipsychotic Agents; Bipolar Disorder; Drug Incompatibility; Drug Therapy, Combination; Dyskinesia, | 1981 |
[Neuroleptic large dose therapy of schizophrenias].
Topics: Acute Disease; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combinat | 1981 |
Neuroleptic-induced acute dyskinesias in rhesus monkeys.
Topics: Acute Disease; Animals; Antipsychotic Agents; Benzamides; Disease Models, Animal; Dyskinesia, Drug-I | 1981 |
Antipsychotic medications: clinical use and effectiveness.
Topics: Antipsychotic Agents; Brain; Dyskinesia, Drug-Induced; Haloperidol; Humans; Neurotransmitter Agents; | 1981 |
Respiratory dyskinesia and dysarthria from prolonged neuroleptic use: tardive dyskinesia?
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dysarthria | 1982 |
[Therapeutic profile of haloperidol].
Topics: Agranulocytosis; Antipsychotic Agents; Chemical and Drug Induced Liver Injury; Drug Eruptions; Drug | 1980 |
Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Dyskinesia, Drug-Induced; Fluphenazine; Haloper | 1983 |
Animal models of tardive dyskinesias.
Topics: Animals; Antipsychotic Agents; Apomorphine; Chlorpromazine; Disease Models, Animal; Dyskinesia, Drug | 1983 |
Reduction of nigral glutamic acid decarboxylase in rats with neuroleptic-induced oral dyskinesia.
Topics: Animals; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Glutamate Decarboxylase; Haloperido | 1983 |
Imaging CNS receptors: the dopaminergic system.
Topics: Animals; Antipsychotic Agents; Apomorphine; Binding Sites; Brain; Carbon Radioisotopes; Deoxyglucose | 1984 |
Narcolepsy, paranoid psychosis, major depression, and tardive dyskinesia.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder; Dextroamphetamine; Dyskinesi | 1984 |
Clinical efficacy, extrapyramidal symptoms and serum levels: influence of administration schedules and concomitant drugs on serum bromperidol concentrations.
Topics: Adult; Biperiden; Brief Psychiatric Rating Scale; Drug Therapy, Combination; Dyskinesia, Drug-Induce | 1984 |
Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration.
Topics: Adult; Aged; Amantadine; Antipsychotic Agents; Dementia; Dose-Response Relationship, Drug; Drug Ther | 1982 |
Molindone compared to haloperidol in a guinea-pig model of tardive dyskinesia.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Guinea Pigs | 1984 |
A model for oral dyskinesia in rats.
Topics: Animals; Cerebral Cortex; Dyskinesia, Drug-Induced; Female; Haloperidol; Mastication; Mouth Diseases | 1982 |
Effects of dopamine agonists, catecholamine depletors, and cholinergic and GABAergic drugs on acute dyskinesias in squirrel monkeys.
Topics: Acute Disease; alpha-Methyltyrosine; Animals; Avoidance Learning; Catecholamines; Dyskinesia, Drug-I | 1984 |
Lithium interferes with reserpine-induced dopamine depletion.
Topics: Adult; Animals; Bipolar Disorder; Corpus Striatum; Dopamine; Dopamine Antagonists; Dyskinesia, Drug- | 1983 |
Toxic irreversible encephalopathy induced by lithium carbonate and haloperidol. A report of 2 cases.
Topics: Adult; Bipolar Disorder; Brain Diseases; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female | 1983 |
Lack of tolerance to haloperidol-induced acute dyskinesias in rhesus monkeys.
Topics: Acute Disease; Animals; Drug Tolerance; Dyskinesia, Drug-Induced; Haloperidol; Macaca mulatta | 1984 |
Similar effect of estradiol and haloperidol on experimental tardive dyskinesia in monkeys.
Topics: Animals; Apomorphine; Drug Interactions; Dyskinesia, Drug-Induced; Estradiol; Female; Haloperidol; M | 1984 |
[Neuroleptic-induced dopaminergic supersensitivity following intermittent and continuous haloperidol administrations in rats].
Topics: Animals; Dyskinesia, Drug-Induced; Haloperidol; Male; Rats; Receptors, Dopamine | 1984 |
Drug holidays alter onset of oral movements in rats following chronic haloperidol.
Topics: Animals; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Mastic | 1984 |
The antidyskinetic action of dihomo-gamma-linolenic acid in the rodent.
Topics: 5,8,11,14-Eicosatetraynoic Acid; 8,11,14-Eicosatrienoic Acid; Animals; Apomorphine; Aspirin; Catalep | 1984 |
Oral tardive dyskinesia in the rat.
Topics: Animals; Apomorphine; Bruxism; Dental Occlusion, Traumatic; Disease Models, Animal; Dyskinesia, Drug | 1983 |
Amantadine in Tourette syndrome.
Topics: Adolescent; Adult; Amantadine; Child; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; H | 1983 |
Effects of electroconvulsive therapy on mood, parkinsonism, and tardive dyskinesia in a depressed patient: ECT and dopamine systems.
Topics: Aged; Brain; Delusions; Depressive Disorder; Dopamine; Dyskinesia, Drug-Induced; Electroconvulsive T | 1983 |
Early onset of severe dyskinesia following lithium-haloperidol treatment.
Topics: Adult; Bipolar Disorder; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haloperidol; Humans; L | 1983 |
SL76002 - effect on gamma-aminobutyric acid and dopamine in animals treated chronically with haloperidol.
Topics: Animals; Brain Chemistry; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Frontal Lobe; gamma-A | 1983 |
Cyclo(Leu-Gly): a possible treatment for tardive dyskinesia?
Topics: Animals; Apomorphine; Corpus Striatum; Dipeptides; Drug Tolerance; Dyskinesia, Drug-Induced; Haloper | 1983 |
Antidyskinetic action of 3-PPP, a selective dopaminergic autoreceptor agonist, in Cebus monkeys with persistent neuroleptic-induced dyskinesias.
Topics: Animals; Cebus; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Fluphenazine; Ha | 1983 |
ECT and tardive dyskinesia.
Topics: Animals; Apomorphine; Dyskinesia, Drug-Induced; Electroconvulsive Therapy; Haloperidol; Humans; Rats | 1984 |
Akathisia with haloperidol and thiothixene.
Topics: Adult; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Thiothixene | 1984 |
Effect of sodium valproate and baclofen in tardive dyskinesia: clinical and neuroendocrine studies.
Topics: Adult; Baclofen; Chronic Disease; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Halop | 1980 |
The effect of some neurotropic drugs on neuroleptic hypersensitivity of dopamine receptors in the central nervous system.
Topics: Adenosine Triphosphate; Animals; Apomorphine; Corpus Striatum; Cyclophosphamide; Drug Hypersensitivi | 1980 |
The effect of drug holidays in an animal model of tardive dyskinesia.
Topics: Animals; Corpus Striatum; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Haloperi | 1980 |
Acute dyskinesias in monkeys elicited by halopemide, mezilamine and the "antidyskinetic" drugs, oxiperomide and tiapride.
Topics: Animals; Avoidance Learning; Benzamides; Benzimidazoles; Domperidone; Dopamine Antagonists; Dyskines | 1981 |
Administering lithium carbonate and haloperidol.
Topics: Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haloperidol; Humans; Lithium; Lithium Carbonate | 1982 |
MK-771 antagonizes the enhanced response to apomorphine in rats treated chronically with haloperidol - implications for tardive dyskinesia.
Topics: Animals; Apomorphine; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Ind | 1982 |
Experimental tardive dyskinesia.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Macaca fascicularis; | 1982 |
Haloperidol-induced tardive dyskinesia in a child with Gilles de la Tourette's disease.
Topics: Child; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Tourette Syndrome | 1980 |
Tardive dyskinesia in persons with Gilles de la Tourette's disease.
Topics: Adolescent; Child; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Middle Aged; Tourette Syndro | 1981 |
Tourette-like syndrome after long-term neuroleptic drug treatment.
Topics: Adult; Chlorpromazine; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Substance Withdrawal Syn | 1982 |
Tardive dyskinesia and chronic neuroleptic treatment of Tourette patients.
Topics: Child; Child, Preschool; Dyskinesia, Drug-Induced; Haloperidol; Humans; Pimozide; Time Factors; Tour | 1982 |
Behavioral effects of haloperidol in young Tourette syndrome patients.
Topics: Adolescent; Adult; Autonomic Nervous System; Behavior; Child; Dyskinesia, Drug-Induced; Fear; Female | 1982 |
The pharmacotherapy of Tourette syndrome.
Topics: Benztropine; Dyskinesia, Drug-Induced; Haloperidol; Humans; Parkinson Disease, Secondary; Tourette S | 1980 |
Tardive dyskinesia, fluphenazine decanoate, and haloperidol.
Topics: Dyskinesia, Drug-Induced; Fluphenazine; Haloperidol; Humans | 1982 |
Prolactin response in tardive dyskinesia.
Topics: Adult; Affective Disorders, Psychotic; Chronic Disease; Dyskinesia, Drug-Induced; Haloperidol; Human | 1982 |
Dislocated jaw concealed by dystonia.
Topics: Adult; Diagnosis, Differential; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Jaw; Joint Di | 1982 |
Mania-induced remission of tardive dyskinesia in manic-depressive illness.
Topics: Adult; Bipolar Disorder; Chlorpromazine; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Remiss | 1982 |
Factors contributing to the up regulation of dopaminergic receptors by chronic haloperidol.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Rats; Rats, Inbred St | 1982 |
Effect of baclofen and haloperidol on gamma-aminobutyric acid and dopamine systems in an animal model of tardive dyskinesia.
Topics: Animals; Baclofen; Brain Chemistry; Disease Models, Animal; Dopamine; Drug Interactions; Dyskinesia, | 1982 |
Estrogen in experimental tardive dyskinesia.
Topics: Animals; Apomorphine; Castration; Dyskinesia, Drug-Induced; Estradiol; Female; Haloperidol; Humans; | 1980 |
Neuroleptic treatment for a substantial proportion of adult life: behavioural sequelae of 9 months haloperidol administration.
Topics: Animals; Behavior, Animal; Drug Tolerance; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Moto | 1980 |
Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dyski | 1981 |
The effect of chronic levodopa on haloperidol induced behavioral supersensitivity in the guinea pig.
Topics: Animals; Apomorphine; Behavior, Animal; Carbidopa; Dyskinesia, Drug-Induced; Guinea Pigs; Haloperido | 1981 |
Delirium and stereotypy from anticholinergic antiparkinson drugs.
Topics: Adult; Aged; Benztropine; Delirium; Diazepam; Drug Therapy, Combination; Dyskinesia, Drug-Induced; E | 1982 |
Analysis of single, double-blind procedures, maintenance of placebo effects, and drug-induced dyskinesia with mentally retarded persons--a brief report [proceedings].
Topics: Adolescent; Adult; Aged; Chlorpromazine; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Halo | 1981 |
Animal models of tardive dyskinesia [proceedings].
Topics: Animals; Cebidae; Cebus; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Humans; Rats | 1981 |
Mobilization of refractory chronic schizophrenics with haloperidol.
Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Haloperi | 1980 |
The effect of haloperidol feeding on dopamine receptor number in ten mouse strains.
Topics: Animals; Dyskinesia, Drug-Induced; Haloperidol; Male; Mice; Mice, Inbred Strains; Models, Neurologic | 1981 |
Receptor techniques in the study of plasma levels of neuroleptics and antidepressant drugs.
Topics: Chromatography, Gas; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Humans | 1980 |
Analysis of single-double blind procedures, maintenance of placebo effects and drug induced dyskinesia with mentally retarded persons.
Topics: Adult; Aged; Chlorpromazine; Double-Blind Method; Drug Evaluation; Dyskinesia, Drug-Induced; Female; | 1980 |
Haloperidol-induced tardive dyskinesia in a 10-year-old girl.
Topics: Child; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Psychotic Disorders | 1980 |
Assessment and treatment of drug-induced tremor.
Topics: Aged; Benztropine; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Paranoid Disorders; Physos | 1980 |
The rat model of tardive dyskinesia: relationship between vacuous chewing movements and gross motor activity during acute and long-term haloperidol treatment.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Mastication; Motor A | 1995 |
Haloperidol-related dyskinesias and pre- and perinatal complications in autistic children.
Topics: Autistic Disorder; Child; Child, Preschool; Diagnosis, Differential; Dyskinesia, Drug-Induced; Femal | 1995 |
Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Antipsychotic Agents; Dep | 1995 |
Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias.
Topics: Animals; Basal Ganglia Diseases; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Glutamate Decarb | 1994 |
Schizophrenia and severe tardive dyskinesia responsive to risperidone.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Hal | 1994 |
Expression of glutamic acid decarboxylase mRNA in striatum and pallidum in an animal model of tardive dyskinesia.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression; Globus Pal | 1995 |
Ultrastructural correlates of haloperidol-induced oral dyskinesias in rat striatum.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Dyskinesia, Drug-Induced; Haloperidol; Male; Micros | 1995 |
Clozapine in tardive Tourette syndrome.
Topics: Adult; Antipsychotic Agents; Clozapine; Dyskinesia, Drug-Induced; Haloperidol; Humans; Injections, I | 1995 |
Neuroleptics up-regulate adenosine A2a receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Binding Sites; Binding, Competitive; Corpus Striatum; Dyskinesia, Dru | 1995 |
Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperi | 1995 |
Persistent oral dyskinesias in haloperidol-withdrawn neonatal 6-hydroxydopamine-lesioned rats.
Topics: Animals; Animals, Newborn; Dyskinesia, Drug-Induced; Haloperidol; Mouth; Oxidopamine; Rats; Rats, Sp | 1994 |
Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose.
Topics: Animals; Delayed-Action Preparations; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Ha | 1995 |
Suppression of haloperidol-induced oral dyskinesias in rats by vigabatrin.
Topics: 4-Aminobutyrate Transaminase; Animals; Anticonvulsants; Body Weight; Brain; Dyskinesia, Drug-Induced | 1995 |
Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Benzazepines; Dyskinesia, Drug-Induced; Haloperidol; M | 1995 |
Diurnal variation in tardive dyskinesia.
Topics: Adult; Chronic Disease; Circadian Rhythm; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Mal | 1995 |
Anticholinergic syndrome. Avoiding misdiagnosis.
Topics: Adolescent; Benztropine; Cholinergic Antagonists; Dose-Response Relationship, Drug; Drug Therapy, Co | 1994 |
Tardive dyskinesia: behavioral effects of repeated intracerebroventricular haloperidol injections in rats do not confirm the kindling hypothesis.
Topics: Animals; Behavior, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Injections, Intraventricul | 1994 |
D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects.
Topics: Adult; Basal Ganglia Diseases; Clozapine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced | 1994 |
Felbamate, an anti-convulsive drug, has anti-parkinsonian potential in rats.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Benzazepines; Catalepsy; Dopamine D2 Receptor Antago | 1994 |
Persistent vacuous chewing in rats following neuroleptic treatment: relationship to dopaminergic and cholinergic function.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Apomorphi | 1993 |
Tiagabine inhibits haloperidol-induced oral dyskinesias in rats.
Topics: Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Amino | 1994 |
The relationship between motor effects in rats following acute and chronic haloperidol treatment.
Topics: Acute Disease; Animals; Catalepsy; Chronic Disease; Disease Models, Animal; Dyskinesia, Drug-Induced | 1994 |
Subjective response to neuroleptics in schizophrenia.
Topics: Adult; Affective Symptoms; Antipsychotic Agents; Chlorpromazine; Dyskinesia, Drug-Induced; Female; H | 1993 |
Movement disorders in patients treated with long-acting injectable antipsychotic drugs.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Female; Fluphenazine; | 1994 |
Dopaminergic stimulation of subthalamic nucleus elicits oral dyskinesia in rats.
Topics: Animals; Apomorphine; Benzazepines; Dopamine Agents; Dyskinesia, Drug-Induced; Haloperidol; Kainic A | 1994 |
Overflow movements may predict neuroleptic-induced dystonia.
Topics: Adolescent; Adult; Bipolar Disorder; Dyskinesia, Drug-Induced; Dystonia; Haloperidol; Humans; Male; | 1994 |
Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja.
Topics: Animals; Caudate Nucleus; Clozapine; DNA-Binding Proteins; Dyskinesia, Drug-Induced; Early Growth Re | 1994 |
Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol.
Topics: Administration, Oral; Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Benzothiazoles; | 1993 |
Basal ganglia iron in tardive dyskinesia: an MRI study.
Topics: Adult; Basal Ganglia; Dominance, Cerebral; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Ir | 1994 |
Basal ganglia GABAA and dopamine D1 binding site correlates of haloperidol-induced oral dyskinesias in rat.
Topics: Animals; Basal Ganglia; Binding Sites; Brain; Dyskinesia, Drug-Induced; Haloperidol; Male; Mouth; Or | 1994 |
Assessment of striatal extracellular dopamine and dopamine metabolites by microdialysis in haloperidol-treated rats exhibiting oral dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-In | 1993 |
Dysregulation of striato-nigral GABAergic pathway by chronic haloperidol treatment: the role of dopamine D1 receptor in the substantia nigra pars reticulata on the development of tardive dyskinesia.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haloperidol; Male; Mast | 1993 |
Vitamin E attenuates the development of haloperidol-induced dopaminergic hypersensitivity in rats: possible implications for tardive dyskinesia.
Topics: Animals; Apomorphine; Behavior, Animal; Dopamine; Dyskinesia, Drug-Induced; Grooming; Haloperidol; M | 1993 |
Stereotyped hand clasping: an unusual tardive movement disorder.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; | 1993 |
Effects of chronic naloxone administration on vacuous chewing movements and catalepsy in rats treated with long-term haloperidol decanoate.
Topics: Animals; Anti-Dyskinesia Agents; Catalepsy; Dyskinesia, Drug-Induced; Grooming; Haloperidol; Male; N | 1995 |
Increase of serum creatine phosphokinase in catatonia: an investigation in 32 acute catatonic patients.
Topics: Acute Disease; Adult; Antipsychotic Agents; Catatonia; Combined Modality Therapy; Creatine Kinase; D | 1996 |
[Tardive dyskinesia: an increased risk of neuroleptics in elderly women].
Topics: Aged; Antipsychotic Agents; Depression; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans | 1995 |
Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Caudate Nucleus; Dyskinesia, Drug-Induced; Female; | 1996 |
Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induc | 1996 |
Autoradiographic mapping of mu opioid receptor changes in rat brain after long-term haloperidol treatment: relationship to the development of vacuous chewing movements.
Topics: Animals; Antipsychotic Agents; Autoradiography; Brain; Dopamine Antagonists; Dyskinesia, Drug-Induce | 1996 |
The dose-response characteristics of rat oral dyskinesias with chronic haloperidol or clozapine administration.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Dy | 1997 |
The behavioural effects of pramipexole, a novel dopamine receptor agonist.
Topics: Animals; Antiparkinson Agents; Benzazepines; Benzothiazoles; Body Temperature; Catalepsy; Clozapine; | 1997 |
Single restraint stress sensitizes acute chewing movements induced by haloperidol, but not if the 5-HT1A agonist 8-OH-DPAT is given prior to stress.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Behavior, Animal; Catalepsy; | 1997 |
Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Dyskinesia, Drug-Induced; Female; | 1997 |
Severe extrapyramidal side effects when discontinuing clozapine and starting haloperidol.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Administration Schedule; Drug Therapy, Combination; Dys | 1997 |
Effects of perospirone (SM-9018), a potential atypical neuroleptic, on dopamine D1 receptor-mediated vacuous chewing movement in rats: a role of 5-HT2 receptor blocking activity.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Avoidance | 1997 |
The effect of chronic haloperidol treatment on dendritic spines in the rat striatum.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dendrites; Dyskinesia, Drug-Induced; Haloperidol; Male; | 1997 |
Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Weight; Dose-Response Relationship, Drug; Dyskinesia, | 1997 |
The common marmoset (Callithrix jacchus) as a model for neuroleptic-induced acute dystonia.
Topics: Acute Disease; Animals; Antipsychotic Agents; Callithrix; Cholinergic Antagonists; Dose-Response Rel | 1997 |
Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Binding, Competitive; Biogenic Monoamines; Dopamine Uptake Inhibitors | 1998 |
Tardive dyskinesia in dopa-responsive dystonia: a reappraisal of the dopamine hypothesis of tardive dyskinesia.
Topics: Adult; Anti-Dyskinesia Agents; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Dystonia; Family | 1998 |
In vivo analysis of hydrogen peroxide and lipid radicals in the striatum of rats under long-term administration of a neuroleptic.
Topics: Animals; Antipsychotic Agents; Corpus Striatum; Drug Administration Schedule; Dyskinesia, Drug-Induc | 1998 |
Emergence of oral and locomotor activity in chronic haloperidol-treated rats following cortical N-methyl-D-aspartate stimulation.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Moto | 1998 |
Mixture in the distribution of haloperidol-induced oral dyskinesias in the rat supports an animal model of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Male; | 1998 |
Chronic haloperidol produces a time- and dose-related slowing of lick rhythm in rats: implications for rodent models of tardive dyskinesia and neuroleptic-induced parkinsonism.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, | 1998 |
Study on the suitability of a rat model for tardive dyskinesia and the preventive effects of various drugs.
Topics: Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Disease Models, Animal; Dyskinesia, Drug-Indu | 1998 |
Failure to down regulate NMDA receptors in the striatum and nucleus accumbens associated with neuroleptic-induced dyskinesia.
Topics: Animals; Antipsychotic Agents; Corpus Striatum; Dizocilpine Maleate; Down-Regulation; Dyskinesia, Dr | 1998 |
Olanzapine for the treatment of tardive dyskinesia.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Biperiden; Dyskinesia, Drug-Induced; Female; Haloperido | 1998 |
Oral Dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid.
Topics: Analysis of Variance; Animals; Anti-Dyskinesia Agents; Antihypertensive Agents; Behavior, Animal; Co | 1998 |
Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Haloperidol; Imidazoles; I | 1998 |
Delirium and persistent dyskinesia induced by a lithium-neuroleptic interaction.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Delirium; Dyskinesia, Drug-Induced; Female | 1998 |
An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol.
Topics: Adult; Antipsychotic Agents; Asian; Cross-Cultural Comparison; Dose-Response Relationship, Drug; Dys | 1998 |
The relationship between oral dyskinesias produced by long-term haloperidol treatment, the density of striatal preproenkephalin messenger RNA and enkephalin peptide, and the number of striatal neurons expressing preproenkephalin messenger RNA in rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enkephalins; Fasciculati | 1999 |
Chronic oral haloperidol and clozapine in rats: A behavioral evaluation.
Topics: Administration, Oral; Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Clozapi | 1999 |
Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients.
Topics: Aged; Antipsychotic Agents; Chi-Square Distribution; Dyskinesia, Drug-Induced; Female; Haloperidol; | 1999 |
Clinical and neuropathological abnormalities in baboons treated with HPTP, the tetrahydropyridine analog of haloperidol.
Topics: Animals; Antipsychotic Agents; Dyskinesia, Drug-Induced; Facial Muscles; Haloperidol; Hypothalamus; | 1999 |
Coenzyme Q10 does not prevent oral dyskinesias induced by long-term haloperidol treatment of rats.
Topics: Animals; Antioxidants; Antipsychotic Agents; Behavior, Animal; Biological Availability; Brain; Coenz | 1999 |
Reserpine treatment of comorbid Tourette's disorder and tardive dystonia.
Topics: Adrenergic Uptake Inhibitors; Adult; Comorbidity; Dyskinesia, Drug-Induced; Dystonia; Haloperidol; H | 1999 |
Effects of chronic haloperidol and clozapine on vacuous chewing and dopamine-mediated jaw movements in rats: evaluation of a revised animal model of tardive dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; | 1999 |
Reduced number of striatal neurons expressing preprosomatostatin mRNA in rats with oral dyskinesias after long-term haloperidol administration.
Topics: Animals; Dyskinesia, Drug-Induced; Female; Haloperidol; Neostriatum; Neurons; Protein Precursors; Ra | 2000 |
No changes in dopamine D(1) receptor mRNA expressing neurons in the dorsal striatum of rats with oral movements induced by long-term haloperidol administration.
Topics: Animals; Cell Count; Dopamine Antagonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; F | 2000 |
["More is less": a retrospective study of haloperidol dosages in acute schizophrenia].
Topics: Acute Disease; Anti-Anxiety Agents; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Dos | 2000 |
Carbamazepine reduces dopamine-mediated behavior in chronic neuroleptic-treated and untreated rats: implications for treatment of tardive dyskinesia and hyperdopaminergic states.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Behavior, Animal; Carbamazepine; Dopamine; Dopamine | 2000 |
Mitochondrial ultrastructure and density in a primate model of persistent tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Basal Ganglia; Caudate Nucleus; Dyskinesia, Drug-Induced; Haloperidol | 2000 |
Olanzapine and tardive dyskinesia.
Topics: Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Pi | 1999 |
Withdrawal-associated changes in peripheral nitrogen oxides and striatal cyclic GMP after chronic haloperidol treatment.
Topics: Animals; Antipsychotic Agents; Brain Mapping; Corpus Striatum; Cyclic GMP; Dyskinesia, Drug-Induced; | 2000 |
Decreased mu-opioid receptor binding in the globus pallidus of rats treated with chronic haloperidol.
Topics: Animals; Antipsychotic Agents; Autoradiography; Behavior, Animal; Dyskinesia, Drug-Induced; Enkephal | 2000 |
Persistent alterations in dendrites, spines, and dynorphinergic synapses in the nucleus accumbens shell of rats with neuroleptic-induced dyskinesias.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Dendrites; Disease Models, Animal; Dynorphins; Dysk | 2000 |
Effect of chronic olanzapine treatment on striatal synaptic organization.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Haloperidol; Male; Neostri | 2001 |
Changes in the pattern of brain-derived neurotrophic factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment.
Topics: Amygdala; Animals; Brain; Brain-Derived Neurotrophic Factor; Drug Administration Schedule; Dyskinesi | 2001 |
Chronic haloperidol-induced alterations in pallidal GABA and striatal D(1)-mediated dopamine turnover as measured by dual probe microdialysis in rats.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Antagonists; Dyskinesia, Drug-Induced; Female; gamma-Am | 2000 |
Drug review "surprises" reader.
Topics: Aged; Alanine Transaminase; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Drug In | 2000 |
Haloperidol-induced neurotoxicity--possible implications for tardive dyskinesia.
Topics: Acetylcysteine; Animals; Antipsychotic Agents; Apoptosis; Brain; Cell Survival; Cells, Cultured; Dys | 2000 |
Piracetam in the treatment of tardive dyskinesia and akathisia: a case report.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Dyskinesia, Drug-Induced; Haloperidol; Humans; | 2001 |
Nitric oxide synthase inhibitors cause motor deficits in mice.
Topics: Animals; Brain Chemistry; Catalepsy; Dopamine; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enzym | 2001 |
Olanzapine in the treatment of tardive dyskinesia: a report of 2 cases.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; | 2001 |
Early suppression of striatal cyclic GMP may predetermine the induction and severity of chronic haloperidol-induced vacous chewing movements.
Topics: Animals; Chronic Disease; Corpus Striatum; Cyclic GMP; Dopamine Antagonists; Dyskinesia, Drug-Induce | 2000 |
Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug- | 2001 |
Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide.
Topics: Animals; Antipsychotic Agents; Calcium; Dyskinesia, Drug-Induced; Glutamic Acid; Haloperidol; Male; | 2001 |
Oral dyskinesias and morphological changes in rat striatum during long-term haloperidol administration.
Topics: Animals; Antipsychotic Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Glutamic Acid; Hal | 2001 |
Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats.
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Catalepsy; Dyskinesia, Drug-Induced; Electromyo | 2001 |
Possible involvement of prostaglandins in haloperidol-induced orofacial dyskinesia in rats.
Topics: Animals; Behavior, Animal; Catalepsy; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; D | 2001 |
Decreased pallidal GABA following reverse microdialysis with clozapine, but not haloperidol.
Topics: Animals; Antipsychotic Agents; Calcium; Clozapine; Dose-Response Relationship, Drug; Down-Regulation | 2001 |
[Emerging lingual dyskinesia versus isolated dysarthria].
Topics: Aged; Anti-Dyskinesia Agents; Diagnosis, Differential; Dysarthria; Dyskinesia, Drug-Induced; Female; | 2001 |
Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements.
Topics: Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperid | 2001 |
Acute administration of haloperidol induces apoptosis of neurones in the striatum and substantia nigra in the rat.
Topics: Animals; Antigens, CD; Antigens, Neoplasm; Antigens, Surface; Apoptosis; Avian Proteins; Basigin; Be | 2002 |
Acute buspirone abolishes the expression of behavioral dopaminergic supersensitivity in mice.
Topics: Animals; Anti-Anxiety Agents; Behavior, Animal; Buspirone; Dopamine; Dopamine Antagonists; Drug Hype | 2002 |
Differential effects of typical and atypical antipsychotic drugs on striosome and matrix compartments of the striatum.
Topics: Animals; Antipsychotic Agents; Clozapine; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonist | 2002 |
Tardive dyskinesia model in the common marmoset.
Topics: Animals; Biperiden; Callithrix; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug | 2002 |
Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to "early onset" vacuous chewing.
Topics: Amisulpride; Animals; Antipsychotic Agents; Clozapine; Dopamine; Dose-Response Relationship, Drug; D | 2002 |
Effect of Withania somnifera glycowithanolides on a rat model of tardive dyskinesia.
Topics: Animals; Anti-Dyskinesia Agents; Anticonvulsants; Antioxidants; Disease Models, Animal; Dyskinesia, | 2002 |
Evaluation of the neurotoxic activity of typical and atypical neuroleptics: relevance to iatrogenic extrapyramidal symptoms.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Cell Cycle; Cell Survival; Clozapine; | 2001 |
Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Corpus Striatum; Dysk | 2002 |
A pharmacologic model of Huntington's chorea.
Topics: Animals; Carbachol; Catheterization; Clozapine; Corpus Striatum; Disease Models, Animal; Dyskinesia, | 1976 |
Drug therapy of tardive dyskinesia.
Topics: Age Factors; Antipsychotic Agents; Brain; Dopamine; Dyskinesia, Drug-Induced; Haloperidol; Humans; L | 1977 |
Tardive dyskinesia: are first signs reversible?
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Dyskinesia, Drug-Induced; Female; Fluphenazine; Haloper | 1977 |
Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects.
Topics: Animals; Antipsychotic Agents; Atropine; Basal Ganglia Diseases; Clozapine; Corpus Striatum; Drug In | 1976 |
Paradoxical response to dopamine agonists in tardive dyskinesia.
Topics: Adrenergic alpha-Agonists; Adult; Amantadine; Apomorphine; Benztropine; Clozapine; Deanol; Dextroamp | 1977 |
Tardive dyskinesia and antihistamines.
Topics: Dyskinesia, Drug-Induced; Haloperidol; Histamine H1 Antagonists; Humans; Male; Middle Aged | 1978 |
Changes in dopamine-dependent motor behaviour caused by propranolol and its isomers.
Topics: Animals; Apomorphine; Dopamine; Dyskinesia, Drug-Induced; Guinea Pigs; Haloperidol; Mice; Motor Acti | 1978 |
Long term treatment of tardive dyskinesia.
Topics: Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesi | 1979 |
Biochemical methods for predicting the occurrence of tardive dyskinesia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Atropine; Caudate Nucleus; Dyskinesia, Drug-Induced; Hal | 1979 |
Normal prolactin responses in tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Middle Aged; Prola | 1979 |
Toxic reactions to lithium and haloperidol.
Topics: Adolescent; Adult; Bipolar Disorder; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug- | 1976 |
Development of acute dystonia and tardive dyskinesia in cebus monkeys.
Topics: Animals; Dyskinesia, Drug-Induced; Dystonia; Haloperidol; Haplorhini; Motor Activity; Time Factors | 1979 |
Pharmacological modification of experimental tardive dyskinesia.
Topics: Animals; Brain; Dyskinesia, Drug-Induced; Haloperidol; Haplorhini; Receptors, Cholinergic; Receptors | 1979 |
Treatment of dyskinetic and choreatic movement disorders in adults.
Topics: Adult; Aged; Athetosis; Chorea; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskine | 1978 |
Gilles de la Tourette's syndrome, tardive dyskinesia, and psychosis in an adolescent.
Topics: Adolescent; Cognition Disorders; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloper | 1978 |
Haloperidol-induced dyskinesias in the monkey.
Topics: Animals; Brain; Dyskinesia, Drug-Induced; Haloperidol; Haplorhini; Harmaline; Macaca; Tremor | 1977 |
Tardive dyskinesia in young adults.
Topics: Adult; Age Factors; Dyskinesia, Drug-Induced; Haloperidol; Humans; Long-Term Care; Male; Schizophren | 1977 |
Dyskinesias evoked in monkeys by weekly administration of haloperidol.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Haplorhini; Time Factors | 1978 |
Dopamine agonists reverse the elevated 3H-neuroleptic binding in neuroleptic-pretreated rats.
Topics: Animals; Apomorphine; Bromocriptine; Carbidopa; Corpus Striatum; Dyskinesia, Drug-Induced; Haloperid | 1979 |
Clinical and experimental studies of phenytoin-induced hyperkinesias.
Topics: Aged; Animals; Apomorphine; Basal Ganglia; Corpus Striatum; Dextroamphetamine; Disease Models, Anima | 1979 |
Choreiform movements induced by anticholinergic therapy.
Topics: Adolescent; Benztropine; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Parasympatholytics; Su | 1979 |
Use of MAO inhibitors in elderly patients.
Topics: Aged; Depression; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; | 1979 |
The effect of metoclopramide and haloperidol on tardive dyskinesia [proceedings].
Topics: Aged; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Metoclopramide; Middle Aged | 1979 |
Choline chloride in animal models of tardive dyskinesia.
Topics: Animals; Apomorphine; Choline; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Humans | 1978 |
The effect of lithium on an animal model of tardive dyskinesia.
Topics: Animals; Apomorphine; Dextroamphetamine; Disease Models, Animal; Dyskinesia, Drug-Induced; Guinea Pi | 1977 |
Dopamine binding following prolonged haloperidol pretreatment.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Haloperidol; In Vitro Techniques; Male; Nucleus | 1978 |
Striatal membrane 3H-dopamine binding in an animal model of tardive dyskinesia.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Guinea Pigs; H | 1978 |
Haloperidol: twenty years' clinical experience.
Topics: Antiparkinson Agents; Biotransformation; Blood Pressure; Dose-Response Relationship, Drug; Drug Inte | 1978 |
Dyskinesias in monkeys: interaction of methamphetamine with prior methadone treatment.
Topics: Animals; Chlorpromazine; Clozapine; Diazepam; Dyskinesia, Drug-Induced; Haloperidol; Haplorhini; Hum | 1976 |
Haloperidol-induced tardive dyskinesia in monkeys.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Haplorhini; Macaca f | 1976 |
Susceptibility to amphetamine-elicited dyskinesias following chronic methadone treatment in monkeys.
Topics: Animals; Chlorpromazine; Clozapine; Diazepam; Drug Interactions; Dyskinesia, Drug-Induced; Haloperid | 1976 |
Coexisting tardive dyskinesia and parkinsonism: a case report.
Topics: Acetylcholine; Adult; Benztropine; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Fluphenazine | 1977 |
Tardive dyskinesia with low-dose, short-term neuroleptic therapy.
Topics: Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Middle Aged; Paranoid Disorders | 1976 |
Diazepam in the treatment of tardive dyskinesia. Preliminary observations.
Topics: Adult; Chlorpromazine; Diazepam; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Schizo | 1976 |
Haloperidol update: 1975.
Topics: Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Haloperidol; Humans; Mental Disorders; Parkinson D | 1976 |
A study on the action of two calcium channel blockers (verapamil and flunarizine) upon an experimental model of tardive dyskinesia in rats.
Topics: Animals; Apomorphine; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Flunarizine; Haloperid | 1992 |
A ketamine-induced rat model of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Clozapine; Dizocilpine Maleate; Dyskinesia, Drug-Induced; Haloperidol | 1992 |
Haloperidol-induced vacuous chewing in rats: suppression by alpha-methyl-tyrosine.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; alpha-Methyltyrosine; Animals; Antipsych | 1992 |
Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzothiazoles; Corpus Striatum; Dihydroxyphenylalanine; Do | 1992 |
Psychotic symptoms preceding ocular deviation in a patient with tardive oculogyric crises.
Topics: Adult; Antipsychotic Agents; Benztropine; Chlorpromazine; Dose-Response Relationship, Drug; Dyskines | 1992 |
Effect of D1 and D2 agonists in primates withdrawn from long-term treatment with haloperidol: the potential role of dopamine D1 receptors in dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; | 1992 |
SCH 39166, a potential antipsychotic drug, does not evoke movement disorders in cebus monkeys.
Topics: Animals; Behavior, Animal; Benzazepines; Cebus; Dopamine Antagonists; Dyskinesia, Drug-Induced; Fema | 1992 |
[Extrapyramidal movement disorders after "Isostar Cocktail"].
Topics: Adolescent; Basal Ganglia Diseases; Beverages; Biperiden; Dyskinesia, Drug-Induced; Food Contaminati | 1992 |
Clozapine in the treatment of psychosis in an 82-year-old woman with tardive dyskinesia.
Topics: Age Factors; Aged; Aged, 80 and over; Clozapine; Dyskinesia, Drug-Induced; Female; Haloperidol; Huma | 1992 |
Neuroleptic-induced dislocation of the jaw.
Topics: Adult; Clonazepam; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haloperidol; Humans; Joint D | 1992 |
Effect of haloperidol and clozapine on the density of "perforated" synapses in caudate, nucleus accumbens, and medial prefrontal cortex.
Topics: Animals; Benzamides; Benzazepines; Brain; Caudate Nucleus; Clozapine; Dopamine Antagonists; Dyskines | 1992 |
Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; | 1992 |
Tardive dyskinesia in the elderly patient.
Topics: Aged; Chlorpromazine; Chronic Disease; Clonazepam; Clozapine; Depressive Disorder; Desipramine; Diph | 1992 |
Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia.
Topics: Adult; Aged; Apomorphine; Brain; Dyskinesia, Drug-Induced; Haloperidol; Homovanillic Acid; Humans; M | 1992 |
Quantitative light microscopic demonstration of increased pallidal and striatal met5-enkephalin-like immunoreactivity in rats following chronic treatment with haloperidol but not with clozapine: implications for the pathogenesis of neuroleptic-induced mov
Topics: Animals; Clozapine; Corpus Striatum; Disease Models, Animal; Drug Administration Schedule; Dyskinesi | 1992 |
Neuroleptic dysphoria.
Topics: Affective Symptoms; Animals; Antipsychotic Agents; Arousal; Dyskinesia, Drug-Induced; Haloperidol; H | 1991 |
Naloxone prevents and blocks the emergence of neuroleptic-mediated oral stereotypic behaviors.
Topics: Animals; Antipsychotic Agents; Dextroamphetamine; Dyskinesia, Drug-Induced; Haloperidol; Male; Nalid | 1991 |
Diltiazem suppresses quinpirole-induced oral stereotypies in haloperidol withdrawn rats.
Topics: Analysis of Variance; Animals; Diltiazem; Dopamine Agents; Dyskinesia, Drug-Induced; Ergolines; Halo | 1991 |
Dopaminergic activity and idiopathic edema.
Topics: Adult; Brain; Diuresis; Dopamine; Dyskinesia, Drug-Induced; Edema; Female; Galactorrhea; Haloperidol | 1991 |
Factors related to haloperidol response and dyskinesias in autistic children.
Topics: Autistic Disorder; Child, Preschool; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Infant; | 1991 |
[Central anticholinergic intoxication syndrome. A contribution to the differential diagnosis of exogenous psychoses].
Topics: Akathisia, Drug-Induced; Biperiden; Diagnosis, Differential; Doxepin; Dysarthria; Dyskinesia, Drug-I | 1991 |
Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys.
Topics: Animals; Antipsychotic Agents; Arousal; Benzamides; Cebus; Disease Models, Animal; Dyskinesia, Drug- | 1990 |
Neurologic approach to drug-induced movement disorders: a study of 125 patients.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amitriptyline; Antipsychotic Agents; Chorea | 1990 |
Tardive dyskinesia presenting as gastrointestinal disorder.
Topics: Antipsychotic Agents; Diagnosis, Differential; Digestive System; Dyskinesia, Drug-Induced; Gastroint | 1990 |
Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats.
Topics: Animals; Antipsychotic Agents; Brain Chemistry; Clozapine; Dyskinesia, Drug-Induced; Female; Haloper | 1990 |
Drug-induced purposeless chewing: animal model of dyskinesia or nausea?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Disease M | 1990 |
Predicting neuroleptic response from a combination of multilevel variables in acute schizophrenic patients.
Topics: Activities of Daily Living; Acute Disease; Adult; Antipsychotic Agents; Dopamine beta-Hydroxylase; D | 1990 |
Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains.
Topics: Animals; Antipsychotic Agents; Atropine; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperid | 1990 |
Tardive dyskinesia in a patient taking haloperidol and fluoxetine.
Topics: Adult; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Fluoxe | 1991 |
Neuroleptic malignant syndrome (NMS): challenge with zuclopenthixol and follow-up--a case report.
Topics: Adult; Clopenthixol; Dyskinesia, Drug-Induced; Electroencephalography; Female; Haloperidol; Humans; | 1990 |
Effects of long-term administration of haloperidol on electrophysiologic properties of rat mesencephalic neurons.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Haloperidol; Male; Mesencephalon; Neurons; Rats; | 1990 |
SCH 23390: D-1 modulation of oral dyskinesias induced in snakes by Xenopus skin mucus.
Topics: Animals; Behavior, Animal; Benzazepines; Dyskinesia, Drug-Induced; Haloperidol; Mucus; Receptors, Do | 1990 |
EPS, NMS, and AIDS.
Topics: Adult; AIDS Dementia Complex; Atrophy; Cerebral Cortex; Dyskinesia, Drug-Induced; Haloperidol; Human | 1990 |
Stereotypies and tardive dyskinesia: abnormal movements in autistic children.
Topics: Adolescent; Autistic Disorder; Child, Preschool; Dyskinesia, Drug-Induced; Haloperidol; Humans; Infa | 1990 |
Increase of spontaneous blink associated with extrapyramidal side effects: a case report.
Topics: Blinking; Chronic Disease; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Middle Aged; Schiz | 1990 |
Spontaneous orofacial dyskinesias in a captive cynomolgus monkey: implications for tardive dyskinesia.
Topics: Animals; Benzazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-In | 1990 |
Tardive eating dystonia.
Topics: Aged; Aggression; Blepharospasm; Deglutition Disorders; Dyskinesia, Drug-Induced; Feeding and Eating | 1990 |
Increased incidence of neuroleptic-induced perioral movements in the rat by hyperglycemia.
Topics: Alloxan; Animals; Blood Glucose; Dyskinesia, Drug-Induced; Female; Haloperidol; Hyperglycemia; Rats; | 1990 |
Intermittent versus continuous neuroleptic treatment in a rat model.
Topics: Animals; Behavior, Animal; Clopenthixol; Drug Administration Schedule; Dyskinesia, Drug-Induced; Hal | 1990 |
Botulinum toxin in treatment of tardive dyskinetic syndrome.
Topics: Aged; Botulinum Toxins; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Injections, Intramusc | 1990 |
Methylazoxymethanol (MAM)-induced brain lesion and oral dyskinesia in rats.
Topics: Animals; Azo Compounds; Behavior, Animal; Brain Diseases; Corpus Striatum; Dyskinesia, Drug-Induced; | 1990 |
Intermittent and continuous haloperidol regimens produce different types of oral dyskinesias in rats.
Topics: Animals; Behavior, Animal; Dyskinesia, Drug-Induced; Female; Fourier Analysis; Grooming; Haloperidol | 1990 |
A new rodent model for neuroleptic-induced pseudo-parkinsonism: low doses of haloperidol increase forelimb tremor in the rat.
Topics: Animals; Atropine; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induce | 1990 |
Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia.
Topics: Animals; Behavior, Animal; Body Weight; Clozapine; Dibenzazepines; Disease Models, Animal; Drinking; | 1990 |
Differentiation of stereotypies from neuroleptic-related dyskinesias in autistic children.
Topics: Autistic Disorder; Blinking; Child; Child, Preschool; Diagnosis, Differential; Dyskinesia, Drug-Indu | 1989 |
[Severe late dyskinesia caused by neuroleptics in a young female. Follow-up and treatment].
Topics: Adolescent; Carbamazepine; Clozapine; Diagnosis, Differential; Dose-Response Relationship, Drug; Dru | 1989 |
Chronic nicotine use blocks haloperidol-induced increase in striatal D2-dopamine receptor density.
Topics: Animals; Body Weight; Corpus Striatum; Dyskinesia, Drug-Induced; Eating; Haloperidol; Male; Nicotine | 1989 |
Continued administration of GM1 ganglioside is required to maintain recovery from neuroleptic-induced sensorimotor deficits in MPTP-treated mice.
Topics: Animals; Brain Diseases; Catalepsy; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; G(M1) Gangl | 1989 |
Chronic neuroleptic treatment in rats produces persisting changes in GABAA and dopamine D-2, but not dopamine D-1 receptors.
Topics: Animals; Autoradiography; Behavior, Animal; Benzazepines; Brain; Disease Models, Animal; Dyskinesia, | 1989 |
Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates.
Topics: Adult; Alprazolam; Antipsychotic Agents; Basal Ganglia Diseases; Drug Synergism; Drug Therapy, Combi | 1989 |
Alterations in sleep polygraphy after neuroleptic withdrawal: a putative supersensitive dopaminergic mechanism.
Topics: Adult; Antipsychotic Agents; Brain; Chronic Disease; Dyskinesia, Drug-Induced; Electroencephalograph | 1989 |
Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; F | 1989 |
Electroencephalographic changes and other indices of neurotoxicity with haloperidol-lithium therapy.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Brain; Dyskinesia, Drug-Induced; Electroencephalograp | 1989 |
Treatment with P-chloroamphetamine enhances the development of neuroleptic-induced orofacial dyskinesias in the rat.
Topics: Amphetamines; Animals; Antipsychotic Agents; Dyskinesia, Drug-Induced; Facial Muscles; Female; Halop | 1989 |
Ketamine-induced tongue protrusions in rats.
Topics: Animals; Deglutition; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Hypoglo | 1989 |
Neuroleptic modulation of oral dyskinesias induced in snakes by Xenopus skin mucus.
Topics: Animals; Behavior, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Ind | 1989 |
[Oral dyskinesia in rats after a single administration of haloperidol combined with GABA-linoleamide. A model of dyskinesia in man].
Topics: Animals; Catalepsy; Disease Models, Animal; Drug Synergism; Dyskinesia, Drug-Induced; gamma-Aminobut | 1989 |
Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy.
Topics: Adult; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Infant; Infant, Newborn; Male; Neonata | 1989 |
Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance.
Topics: Adult; Blood Glucose; Chronic Disease; Diabetes Mellitus, Type 2; Dyskinesia, Drug-Induced; Female; | 1989 |
The pathophysiology of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Chlorpromazine; Corpus Striatum; Disea | 1985 |
Experimental tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Brain; Cebus; Corpus Striatum; Disease Models, Animal; Drug Evaluatio | 1985 |
Interpatient variations in antipsychotic therapy.
Topics: Age Factors; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Dose-Response Relationshi | 1985 |
Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review.
Topics: Animals; Antipsychotic Agents; Benztropine; Cebus; Death, Sudden; Disease Models, Animal; Drug Thera | 1985 |
Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations.
Topics: Administration, Oral; Antipsychotic Agents; Clopenthixol; Delayed-Action Preparations; Dose-Response | 1985 |
Effect of neuroleptics and of potential new antipsychotic agents (MJ 13859-1 and MJ 13980-1) on a monkey model of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Cebus; Chlorpromazine; Clozapine; Dyskinesia, Drug-Induced; Female; H | 1986 |
Tardive dyskinesia: a role for the endogenous opioid system.
Topics: Animals; Antipsychotic Agents; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Endorphins; gamm | 1986 |
Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration.
Topics: Adult; Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Kinetics; | 1986 |
[Changes in the health state of schizophrenic patients in neuroleptic therapy].
Topics: Adolescent; Adult; Antipsychotic Agents; Attitude to Health; Clozapine; Dyskinesia, Drug-Induced; Ha | 1986 |
Tremorous mouth movements in rats administered chronic neuroleptics.
Topics: Animals; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Haloperidol; Mouth; Rats; Rats, Inb | 1987 |
Neuroleptic-induced oral movements in rats: methodological issues.
Topics: Animals; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Fluphenazine; Haloperidol; Methods; | 1987 |
[Neuroleptic modification of basic schizophrenic disorders].
Topics: Adolescent; Adult; Antipsychotic Agents; Clozapine; Dyskinesia, Drug-Induced; Haloperidol; Humans; M | 1987 |
Neuroleptic-induced oral dyskinesias: effects of progabide and lack of correlation with regional changes in glutamic acid decarboxylase and choline acetyltransferase activities.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Brain; Choline O-Acetyltransferase; Dyskinesia, Drug | 1987 |
Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder.
Topics: Acute Disease; Adolescent; Aggression; Akathisia, Drug-Induced; Antipsychotic Agents; Child; Child, | 1988 |
Pisa syndrome. Report of a case.
Topics: Adult; Amisulpride; Antipsychotic Agents; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Schiz | 1988 |
Psychotic patients who become worse on neuroleptics.
Topics: Adolescent; Adult; Antipsychotic Agents; Benztropine; Chlorpromazine; Dyskinesia, Drug-Induced; Fema | 1988 |
Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration.
Topics: Autistic Disorder; Child; Child, Preschool; Drug Administration Schedule; Dyskinesia, Drug-Induced; | 1989 |
Tourette-like symptoms associated with neuroleptic therapy in an autistic child.
Topics: Autistic Disorder; Child, Preschool; Diagnosis, Differential; Dyskinesia, Drug-Induced; Haloperidol; | 1989 |
Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients.
Topics: Drug Administration Schedule; Dyskinesia, Drug-Induced; Haloperidol; Hospitalization; Humans; Male; | 1989 |
Dopaminomimetic action of diphenylhydantoin in rat striatum: effect on homovanillic acid and cyclic AMP levels.
Topics: Animals; Apomorphine; Corpus Striatum; Cyclic AMP; Dyskinesia, Drug-Induced; Haloperidol; Homovanill | 1985 |
Interaction between chronic amphetamine and neuroleptic treatments on oral behavior in rats.
Topics: Amphetamine; Animals; Behavior, Animal; Body Weight; Drug Interactions; Dyskinesia, Drug-Induced; Fe | 1987 |
Clonazepam-haloperidol therapy in schizophrenia.
Topics: Clonazepam; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haloperidol; Humans; Schizophrenia | 1988 |
[Increase in creatine phosphokinase in atypical early neuroleptic dyskinesia].
Topics: Adult; Creatine Kinase; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Psychoses, Alcoholic | 1988 |
Behavioural effects of dopamine D-1 and D-2 receptor agonists in monkeys previously treated with haloperidol.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; | 1988 |
An electrographic characterization of ketamine-induced linguopharyngeal motor activity.
Topics: Animals; Deglutition; Dyskinesia, Drug-Induced; Electromyography; Female; Haloperidol; Ketamine; Rat | 1988 |
Tardive dyskinesia following haloperidol treatment in Tourette's syndrome.
Topics: Adult; Age Factors; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Substance Withdrawal Syndro | 1987 |
Chronic haloperidol effects on oral movements and radial-arm maze performance in rats.
Topics: Animals; Choice Behavior; Dyskinesia, Drug-Induced; Female; Haloperidol; Memory; Motor Activity; Mou | 1987 |
The effects of L-tryptophan on haloperidol-induced movement disorder in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucleus; Dopamine; Dyskinesia, Drug-Induced; Halope | 1987 |
[Value of neuroleptic therapy in the self assessment of schizophrenic patients].
Topics: Clozapine; Depressive Disorder; Dibenzazepines; Dyskinesia, Drug-Induced; Haloperidol; Humans; Psych | 1987 |
Motor effects of calcitonin administered intracerebroventricularly in the rat.
Topics: Animals; Behavior, Animal; Calcitonin; Cerebral Ventricles; Corpus Striatum; Dopamine; Dyskinesia, D | 1986 |
Exacerbation of tardive dyskinesia by Joseph disease.
Topics: Aged; Brain Diseases; Cerebellar Ataxia; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Ment | 1986 |
Differential alterations in striatal acetylcholine function in rats during 12 months' continuous administration of haloperidol, sulpiride, or clozapine.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Choline O-Acetyltransferase; Clozapine; Corpus Striatu | 1986 |
Extrapyramidal reactions to prochlorperazine and haloperidol in the United Kingdom.
Topics: Adolescent; Adult; Age Factors; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Dystonia; Female; | 1986 |
Tardive dyskinesia after low-dose haloperidol.
Topics: Adult; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male | 1987 |
The nullification by diazepam of haloperidol-induced increases in the level of striatal dopamine but not in the activity of glutamic acid decarboxylase.
Topics: Animals; Brain; Corpus Striatum; Diazepam; Dopamine; Dyskinesia, Drug-Induced; Glutamate Decarboxyla | 1986 |
[Vacuous chewing after haloperidol and GABA-linoleamide administration in the rat].
Topics: Animals; Catalepsy; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haloperidol; Mastication; Psy | 1986 |
SCH 23390 dissociated from conventional neuroleptics in apomorphine climbing and primate acute dyskinesia models.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Benzazepines; Benz | 1985 |
Estradiol can suppress haloperidol-induced supersensitivity in dyskinetic monkeys.
Topics: Animals; Apomorphine; Drug Interactions; Dyskinesia, Drug-Induced; Estradiol; Female; Haloperidol; M | 1986 |
Iron pigment in the brain of a man with tardive dyskinesia.
Topics: Basal Ganglia; Bipolar Disorder; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Gliosis; Halop | 1985 |
Long-acting therapy of schizophrenia.
Topics: Adolescent; Adult; Antiparkinson Agents; Benzodiazepines; Biofeedback, Psychology; Bromocriptine; Dy | 1985 |
Rapid induction of extrapyramidal side effects with combined use of lithium and neuroleptics.
Topics: Adult; Chlorpromazine; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Femal | 1985 |
Propranolol-induced tardive dyskinesia in a patient with akathisia.
Topics: Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Middle Aged; Parkinson Disease, Secondary; Pr | 1985 |
[Three cases of lingual ballistic movement followed by a rigid-dystonic state of the tongue].
Topics: Aged; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Movement | 1985 |
Behavioral aspects of serotonin-dopamine interaction in the monkey.
Topics: Animals; Chlorocebus aethiops; Cyproheptadine; Dextroamphetamine; Dopamine; Dyskinesia, Drug-Induced | 1985 |